<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Metab Brain Dis</journal-id><journal-id journal-id-type="iso-abbrev">Metab Brain Dis</journal-id><journal-title-group><journal-title>Metabolic Brain Disease</journal-title></journal-title-group><issn pub-type="ppub">0885-7490</issn><issn pub-type="epub">1573-7365</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39636464</article-id><article-id pub-id-type="pmc">PMC11621172</article-id>
<article-id pub-id-type="publisher-id">1486</article-id><article-id pub-id-type="doi">10.1007/s11011-024-01486-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Bile duct ligation-induced cirrhosis does not alter the blood-brain barrier permeability to sucrose in rats</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Miah</surname><given-names>Mohammad K.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bickel</surname><given-names>Ulrich</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Mehvar</surname><given-names>Reza</given-names></name><address><email>mehvar@chapman.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/033ztpr93</institution-id><institution-id institution-id-type="GRID">grid.416992.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 3554</institution-id><institution>Department of Pharmaceutical Sciences, </institution><institution>Texas Tech University Health Sciences Center, </institution></institution-wrap>Amarillo, Texas USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043cec594</institution-id><institution-id institution-id-type="GRID">grid.418152.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0543 9493</institution-id><institution>Clinical Pharmacology &#x00026; Quantitative Pharmacology, CPSS, </institution><institution>AstraZeneca, </institution></institution-wrap>Boston, Massachusetts USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/033ztpr93</institution-id><institution-id institution-id-type="GRID">grid.416992.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 3554</institution-id><institution>Center for Blood-Brain Barrier Research, </institution><institution>Texas Tech University Health Sciences Center, </institution></institution-wrap>Amarillo, Texas USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0452jzg20</institution-id><institution-id institution-id-type="GRID">grid.254024.5</institution-id><institution-id institution-id-type="ISNI">0000 0000 9006 1798</institution-id><institution>Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, </institution><institution>Chapman University, </institution></institution-wrap>9401 Jeronimo Road, Irvine, California USA </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>40</volume><issue>1</issue><elocation-id>53</elocation-id><history><date date-type="received"><day>4</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Contradictory results have been reported about the effects of liver diseases on the blood-brain barrier (BBB) permeability to markers. For instance, both an increase and no change in the BBB permeability to BBB markers sodium fluorescein and Evans blue have been reported in experimental cholestasis induced by bile duct ligation (BDL) in rats. These contradictory effects might be due to inherent limitations of these markers and/or methodological issues. Here, we investigated the time course of the impact of BDL in rats on BBB permeability using a recently developed stable isotope labeled marker [<sup>13</sup>C]sucrose, which is expected to be devoid of limitations of other markers, such as sodium fluorescein. At various times (five days, two weeks, and four weeks) after BDL or sham surgery, the brain uptake clearance (<italic>K</italic><sub><italic>in</italic></sub>) of [<sup>13</sup>C]sucrose was estimated using quantitation of the marker in plasma, blood, and brain by a specific LC-MS/MS analytical method. BDL caused substantial increases in the plasma concentrations of liver biochemical markers (bilirubin, total bile acids, ammonia, and cholesterol) and reduced liver cytochrome P450 content and metabolic activities. However, compared with the sham group, the plasma or blood AUC, brain concentrations, and <italic>K</italic><sub><italic>in</italic></sub> of [<sup>13</sup>C]sucrose in BDL animals remained unchanged at all the studied times. Additionally, we observed a negative correlation between the sucrose <italic>K</italic><sub><italic>in</italic></sub> and plasma total bile acids concentrations in the BDL animals. It is concluded that cholestatic liver disease, induced by BDL surgery in rats, does not significantly affect the BBB permeability to sucrose up to 4&#x000a0;weeks after the surgery.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s11011-024-01486-6.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Blood-brain barrier permeability</kwd><kwd>Liver cirrhosis</kwd><kwd>Cholestasis</kwd><kwd>Bile duct ligation</kwd><kwd>[<sup>13</sup>C]Sucrose</kwd><kwd>Apparent brain uptake clearance</kwd></kwd-group><funding-group><award-group><funding-source><institution>Chapman University</institution></funding-source></award-group><open-access><p>Open access funding provided by SCELC, Statewide California Electronic Library Consortium</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Liver diseases are known to negatively affect the functions of remote organs, including the brain (D'Mello and Swain <xref ref-type="bibr" rid="CR21">2011</xref>). Various reports have indicated that liver diseases may lead to cognitive impairments and, in severe cases, to hepatic encephalopathy and coma (Butterworth <xref ref-type="bibr" rid="CR6">2013</xref>; Claeys et al. <xref ref-type="bibr" rid="CR14">2021</xref>; Ohikere and Wong <xref ref-type="bibr" rid="CR45">2024</xref>; Prasad et al. <xref ref-type="bibr" rid="CR49">2007</xref>). Despite some controversy (Butterworth <xref ref-type="bibr" rid="CR6">2013</xref>; Nguyen <xref ref-type="bibr" rid="CR42">2012</xref>), it is generally believed that alterations in the blood-brain barrier (BBB) structure and/or function are one of the mechanisms of encephalopathy and coma associated with acute liver failure (Butterworth <xref ref-type="bibr" rid="CR7">2016</xref>; Cauli et al. <xref ref-type="bibr" rid="CR8">2011</xref>; Chastre et al. <xref ref-type="bibr" rid="CR10">2013</xref>; Chen et al. <xref ref-type="bibr" rid="CR12">2009</xref>, <xref ref-type="bibr" rid="CR13">2013</xref>; McMillin et al. <xref ref-type="bibr" rid="CR34">2015</xref>). In addition to acute liver failure, chronic liver diseases, such as cirrhosis, may also be associated with neurological deficits and cognitive decline, potentially leading to hepatic encephalopathy at later stages (Claeys et al. <xref ref-type="bibr" rid="CR14">2021</xref>). However, compared with acute liver failure, the effects of chronic liver diseases on BBB permeability are less understood.</p><p id="Par3">Bile duct-ligated (BDL) rats have been extensively used as a reliable animal model of cholestasis-induced liver injury, resulting in portal inflammation, fibrosis, and secondary biliary cirrhosis (Liu et al. <xref ref-type="bibr" rid="CR32">2013</xref>). Additionally, BDL rats have been used to study the effects of chronic liver diseases on BBB permeability. However, contradictory changes in the BBB permeability to both small and large molecular weight markers have been reported in BDL rats (Bosoi et al. <xref ref-type="bibr" rid="CR5">2012</xref>; Dhanda and Sandhir <xref ref-type="bibr" rid="CR20">2017</xref>; Quinn et al. <xref ref-type="bibr" rid="CR50">2014</xref>; Stewart et al. <xref ref-type="bibr" rid="CR54">1989</xref>; Wahler et al. <xref ref-type="bibr" rid="CR59">1993</xref>; Xu et al. <xref ref-type="bibr" rid="CR64">2016</xref>). For instance, whereas some studies have reported an increase in the BBB permeability to Evans blue (EB) in BDL rats at five days (Quinn et al. <xref ref-type="bibr" rid="CR50">2014</xref>) or four weeks (Dhanda and Sandhir <xref ref-type="bibr" rid="CR20">2017</xref>) after surgery, others (Bosoi et al. <xref ref-type="bibr" rid="CR5">2012</xref>; Xu et al. <xref ref-type="bibr" rid="CR64">2016</xref>) have shown no change in the BBB permeability to this marker at 3, 7, or 14&#x000a0;days (Xu et al. <xref ref-type="bibr" rid="CR64">2016</xref>) or six weeks (Bosoi et al. <xref ref-type="bibr" rid="CR5">2012</xref>) following BDL. Similarly, both an increase (Dhanda and Sandhir <xref ref-type="bibr" rid="CR20">2017</xref>) and no change (Bosoi et al. <xref ref-type="bibr" rid="CR5">2012</xref>) in the BBB permeability to the low molecular weight marker sodium fluorescein (FL) have been reported in 4-week and 6-week BDL rats, respectively. Therefore, it is unclear how the BBB permeability to large and small molecular weight markers may change in this animal model of chronic liver disease.</p><p id="Par4">Our relatively recent studies (Miah et al. <xref ref-type="bibr" rid="CR35">2015</xref>, <xref ref-type="bibr" rid="CR37">2017a</xref>; Shaik et al. <xref ref-type="bibr" rid="CR52">2013</xref>) on the effects of liver diseases on BBB permeability suggest that some of the contradictory results in the literature might be due to the methodological issues related to the method of calculation of BBB permeability changes, shortcomings of the markers, and/or analytical techniques used in these studies. A vast majority of the BBB permeability studies use the changes in the brain concentrations of the markers alone as a measure of alterations in the BBB permeability without consideration of possible changes in the systemic pharmacokinetics and plasma or blood concentrations of the markers. For example, with some exceptions (Wahler et al. <xref ref-type="bibr" rid="CR59">1993</xref>), the vast majority of the reported BBB permeability studies in BDL rats are based only on measuring the concentrations or activity of the markers in the brain alone (Bosoi et al. <xref ref-type="bibr" rid="CR5">2012</xref>; Dhanda and Sandhir <xref ref-type="bibr" rid="CR20">2017</xref>; Quinn et al. <xref ref-type="bibr" rid="CR50">2014</xref>; Stewart et al. <xref ref-type="bibr" rid="CR54">1989</xref>; Xu et al. <xref ref-type="bibr" rid="CR64">2016</xref>). Additionally, the changes in the brain concentrations of markers bound to proteins, such as FL (Miah et al. <xref ref-type="bibr" rid="CR35">2015</xref>) or EB (Saunders et al. <xref ref-type="bibr" rid="CR51">2015</xref>), may be simply due to a change in the protein binding of these markers in different disease states. Lastly, non-specific analytical methods, such as radioactive or fluorometric methods, may contribute to the contradictory results observed in the literature (Miah et al. <xref ref-type="bibr" rid="CR37">2017a</xref>).</p><p id="Par5">We have developed a specific method for measuring the BBB permeability to low MW markers using a stable isotope labeled [<sup>13</sup>C]sucrose (Miah et al. <xref ref-type="bibr" rid="CR36">2016</xref>). The method is based on analyzing the marker in both plasma and brain by a specific LC-MS/MS method. As opposed to the widely-used low MW permeability marker FL, sucrose does not undergo binding to plasma proteins and is not subject to any known BBB transporters (Alqahtani et al. <xref ref-type="bibr" rid="CR2">2018</xref>; Palestine and Brubaker <xref ref-type="bibr" rid="CR47">1982</xref>; Sun et al. <xref ref-type="bibr" rid="CR55">2001</xref>). In this study, we used brain uptake clearance of [<sup>13</sup>C]sucrose, which uses both the brain concentrations and blood or plasma exposure of the marker, to investigate the time course of the effects of cholestatic liver disease on BBB permeability to low MW compounds in BDL rats.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Chemicals and reagents</title><p id="Par6">[UL-<sup>13</sup>C<sub>12</sub>]Sucrose (all the carbons in both glucose and fructose molecules are labeled with <sup>13</sup>C isotope; denoted [<sup>13</sup>C]sucrose) and the internal standard, which was [UL-<sup>13</sup>C<sub>6</sub><sup>fru</sup>]sucrose (all the carbons in the fructose molecule are labeled with <sup>13</sup>C isotope), were purchased from Omicron Biochemicals (South Bend, IN, USA). Cytochrome c, 7-ethoxycoumarin, and 7-hydroxycoumarin were purchased from Sigma-Aldrich (St. Louis, MO, USA). LC-MS grade acetonitrile and water were procured from Fisher Scientific (Hampton, NH, USA). Ketamine and xylazine solutions were purchased from Lloyd Laboratories (Shenandoah, IA, USA). Heparin solution was purchased from APP Pharmaceuticals (Schaumburg, IL, USA). All the other reagents and chemicals were of high purity and purchased from commercially available sources.</p></sec><sec id="Sec4"><title>Animals and bile duct ligation surgery</title><p id="Par7">Adult (255&#x02013;330&#x000a0;g), male Sprague-Dawley rats were purchased from Charles River Laboratory (Wilmington, MA) and acclimated in single, ventilated cages with 12-h dark-light cycles in a temperature- and humidity-controlled room with free access to food and water. All the animal procedures used in this study were approved by Texas Tech University Health Sciences Center&#x02019;s Institutional Animal Care and Use Committee and were consistent with the guidelines set by the Guide for the Care and Use of Laboratory Animals (National Research Council <xref ref-type="bibr" rid="CR40">2011</xref>). Animals were randomly assigned to two groups of bile duct ligation (BDL) and sham surgery (Sham), which were further divided into three groups studied five days, two weeks, or four weeks after the surgery, resulting in a total of six groups (<italic>n</italic>&#x02009;=&#x02009;6&#x02013;7/group).</p><p id="Par8">For bile duct ligation, overnight-fasted rats were anesthetized with ketamine: xylazine (80:8&#x000a0;mg/kg) via intramuscular injection. After opening the abdomen, the common bile duct was doubly ligated close to the liver using two sutures and severed between the ligatures (Klein et al. <xref ref-type="bibr" rid="CR29">2017</xref>). Sham animals underwent laparotomy and manipulation of the bile duct without its ligation or resection. We used ketamine:xylazine because we recently (Noorani et al. <xref ref-type="bibr" rid="CR44">2023</xref>) showed that isoflurane anesthesia causes an opening of the BBB and increases the BBB permeability to sucrose and mannitol by a factor of two. However, ketamine:xylazine anesthesia does not have an impact on BBB permeability.</p></sec><sec id="Sec5"><title>Dosing and sampling</title><p id="Par9">Sham and BDL rats were anesthetized with ketamine: xylazine, and a catheter was placed in their femoral artery for blood sample collection. A single dose (10&#x000a0;mg/kg) of [<sup>13</sup>C]sucrose was administered through the penile vein, and serial blood samples (~&#x02009;0.2&#x000a0;mL) were collected before and at 1, 5, 10, 15, 20, and 30&#x000a0;min following the administration of the marker. A portion of blood was centrifuged for plasma collection, and another portion was used to measure blood concentrations of [<sup>13</sup>C]sucrose. At the end of sampling, a catheter was placed in the left ventricle of the heart, and the whole body was perfused with ice-cold saline at a rate of 25&#x000a0;mL/min for 5&#x000a0;min, and the brain and liver were collected and snap-frozen in cold iso-pentane. All the samples were kept at &#x02013;80&#x000b0;C before analysis.</p></sec><sec id="Sec6"><title>Analysis of [<sup>13</sup>C]sucrose in blood, plasma, and brain</title><p id="Par10">Before analysis, plasma and blood samples were diluted 100- and 50-fold, respectively, with water, and the brain was homogenized in ice-cold water at a ratio of 1:9 to obtain brain homogenate. The concentrations of [<sup>13</sup>C]sucrose in the biological samples were determined using a previously reported validated UPLC-MS/MS method (Miah et al. <xref ref-type="bibr" rid="CR36">2016</xref>). Briefly, diluted blood, plasma, or brain samples (20 &#x000b5;L) were subjected to protein precipitation by the addition of 180 &#x000b5;L of acetonitrile: water (80:20), which contained [UL-<sup>13</sup>C<sub>6</sub><sup>fru</sup>]sucrose as internal standard. The chromatographic separation was performed using an Acquity BEH amide column (50&#x000a0;mm&#x02009;&#x000d7;&#x02009;3&#x000a0;mm, 1.7&#x000a0;&#x000b5;m) and an isocratic mobile phase of acetonitrile: water: ammonium hydroxide (72:28:0.1, v/v), run a flow rate 0.2&#x000a0;mL/min. Column temperature was maintained at 45&#x000a0;&#x000b0;C. The multiple reaction monitoring was in negative mode, and the transitions for [<sup>13</sup>C]sucrose and internal standard were 353&#x02794;92 m/z and 347&#x02794;89 m/z, respectively.</p></sec><sec id="Sec7"><title>Serum biochemical markers</title><p id="Par11">The serum biochemical markers for cholestasis were quantitated using commercial assays according to the manufacturer&#x02019;s instructions. Assay kits for the spectroscopic measurement of total bilirubin (Teco Diagnostics; Anaheim, CA, USA), total bile acids (TBA) (Crystal Chem; Elk Grove Village, IL, USA), and ammonia (Sigma-Aldrich; St. Louis, MO, USA) and fluorometric measurement of cholesterol (Cayman Chemical; Ann Arbor, MI, USA) were used.</p></sec><sec id="Sec8"><title>Liver microsome preparations and cytochrome P450 metabolism studies</title><p id="Par12">Liver microsomes were prepared using standard ultracentrifugation methods (Lake <xref ref-type="bibr" rid="CR31">1987</xref>) and, after suspension in sucrose (250&#x000a0;mM), were stored at &#x02013;80&#x000a0;&#x000b0;C. Total protein content was measured using the Bradford assay kit (Thermo Fisher Scientific, Waltham, MA). Carbon monoxide-bound total P450 contents were determined by Omura and Sato's method (Lake <xref ref-type="bibr" rid="CR31">1987</xref>). Cytochrome P450 reductase (CPR) activity was measured by the reduction of cytochrome c using a kinetic assay, as described before (Guengerich <xref ref-type="bibr" rid="CR25">1994</xref>). Ethoxycoumarin-O-dealkylation (ECOD) activity of the microsomes, as a general marker of the P450 activity (Waxman and Chang <xref ref-type="bibr" rid="CR61">2006</xref>), was determined by the conversion of ethoxycoumarin to hydroxycoumarin and LC-MS/MS measurement of the metabolite, as described in detail before (Chandrashekar et al. <xref ref-type="bibr" rid="CR9">2023</xref>).</p></sec><sec id="Sec9"><title>Pharmacokinetics analysis</title><p id="Par13">The area under the plasma (<inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${AUC}_{0-30}^{plasma}$$\end{document}</tex-math><inline-graphic xlink:href="11011_2024_1486_Article_IEq1.gif"/></alternatives></inline-formula>) or blood (<inline-formula id="IEq2"><alternatives><tex-math id="M2">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${AUC}_{0-30}^{blood}$$\end{document}</tex-math><inline-graphic xlink:href="11011_2024_1486_Article_IEq2.gif"/></alternatives></inline-formula>) concentration-time curve from time zero to the last sampling time (30&#x000a0;min) was calculated by log trapezoidal rule using PKanalix software in the MonolixSuite (SimulationsPlus; Lancaster, CA, USA). To determine the BBB permeability to [<sup>13</sup>C]sucrose, apparent brain uptake clearance (<italic>K</italic><sub><italic>in</italic></sub>) values were estimated based on both plasma (<italic>K</italic><sub><italic>in-plasma</italic></sub>) and blood (<italic>K</italic><sub><italic>in-blood</italic></sub>) AUC data (Bickel <xref ref-type="bibr" rid="CR3">2022</xref>):<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${K}_{in-blood}=\frac{{C}_{30}^{br}}{{AUC}_{0-30}^{blood}}$$\end{document}</tex-math><graphic xlink:href="11011_2024_1486_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M4">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${K}_{in-plasma}=\frac{{C}_{30}^{br}}{{AUC}_{0-30}^{plasma}}$$\end{document}</tex-math><graphic xlink:href="11011_2024_1486_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula></p><p id="Par14">where <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${C}_{30}^{br}$$\end{document}</tex-math><inline-graphic xlink:href="11011_2024_1486_Article_IEq3.gif"/></alternatives></inline-formula> is the terminal brain concentration of the marker after the in-situ removal of the residual blood in the brain.</p></sec><sec id="Sec10"><title>Statistical analysis</title><p id="Par15">Statistical analysis of data was performed using Prism software (GraphPad Software, LaJolla, CA). Two-way ANOVA, followed by Bonferroni multiple comparisons, was used for the comparison of biochemical markers, P450 metabolism parameters, AUC values, brain concentrations, and <italic>K</italic><sub><italic>in</italic></sub> values for Sham and BDL animals at three different time points of five days, two weeks, and four weeks. The relationships between the brain concentration or <italic>K</italic><sub><italic>in</italic></sub> and biochemical parameters were analyzed using linear regression analysis. In all cases, a <italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.05 was considered significant. Data are presented as mean&#x02009;&#x000b1;&#x02009;SD or individual values. All the data were included in the analysis without any attempts at statistical elimination of potential outliers.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Plasma biochemical markers</title><p id="Par16">The plasma levels of cholestasis biomarkers are presented in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. The plasma bilirubin concentrations in BDL animals were substantially (40-50 fold) higher (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) than their corresponding Sham animals for all the three time points of 5 Days, 2 Weeks, and 4 Weeks after the surgery (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). Similarly, the plasma total bile acids (TBA) concentrations in BDL animals were significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) higher (10-13 fold) than those in Sham animals (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b). However, the two-way ANOVA revealed that in addition to the differences between the Sham and BDL groups (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), the time after the surgery also had a significant effect (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) on the results, with a trend toward lower TBA concentrations as the time of surgery progressed from 5&#x000a0;days to 4&#x000a0;weeks (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b). The plasma ammonia levels in BDL animals were also higher (2.4&#x02013;6.6 fold) than those in their corresponding Sham animals in all three time groups but the 2.4-fold difference for the 4 Week group did not reach statistical significance (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05), most likely due to the high variability in the data (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). For plasma cholesterol concentrations, there was only a significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) increase (2.1 fold) in 5 Days BDL rats with no differences between BDL and Sham groups at the other two time points (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>d).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Plasma concentrations of biomarkers of cholestasis, total bilirubin (<bold>a</bold>), TBA (<bold>b</bold>), ammonia (<bold>c</bold>), and cholesterol (<bold>d</bold>), in the bile-duct ligated (BDL) and sham-operated (Sham) animals. Different groups of animals (<italic>n</italic>&#x02009;=&#x02009;6&#x02013;7/group) were subjected to the BDL or sham surgery, and plasma concentrations of the biomarkers were measured five days, two weeks, or four weeks after the surgery. Symbols and horizontal lines represent individual and mean values, respectively. Statistical significance (*, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05; ****, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, and ns, not significant) is based on two-way ANOVA, followed by Bonferroni multiple comparisons of the means</p></caption><graphic xlink:href="11011_2024_1486_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec13"><title>Liver P450 content and activity</title><p id="Par17">The total cytochrome P450 contents (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a), CPR activities (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b), and ECOD activities (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c) for BDL and Sham groups at different time points after the surgery are presented in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. The total cytochrome P450 content was significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) depressed (60&#x02013;70% decline) in BDL animals, compared with their corresponding Sham counterparts, at all the studied time points (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). The CPR activities in BDL animals were also lower than those in Sham animals but the decline (46%) was significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) only for the 5 Days group (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). Similarly, the ECOD activities in BDL groups were lower than those in Sham animals. However, the decrease was significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) only for the 5 Days (68% decline) and the 2 Weeks (61% decline) groups (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Liver microsomal total cytochrome P450 content (<bold>a</bold>), cytochrome P450 reductase (CPR) activity (<bold>b</bold>), and ethoxycoumarin-O-dealkylation (ECOD) activity (<bold>c</bold>) in the bile-duct ligated (BDL) and sham-operated (Sham) animals. Different groups of animals (<italic>n</italic>&#x02009;=&#x02009;6&#x02013;7/group) were subjected to the BDL or sham surgery, and liver microsomes were prepared five days, two weeks, or four weeks after the surgery. Symbols and horizontal lines represent individual and mean values, respectively. Statistical significance (*, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05; **, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; ****, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001; and ns, not significant) is based on two-way ANOVA, followed by Bonferroni multiple comparisons of the means</p></caption><graphic xlink:href="11011_2024_1486_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec14"><title>Pharmacokinetics and brain uptake of [<sup>13</sup>C]sucrose</title><p id="Par18">The plasma concentration&#x02013;time profiles of [<sup>13</sup>C]sucrose for the BDL and Sham groups after five days, two weeks, and four weeks of surgery, along with their respective AUC values, are presented in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. As shown in the figure (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a-c), the plasma concentrations of [<sup>13</sup>C]sucrose in BDL and Sham animals were almost superimposable at all three studied time points, resulting in similar <inline-formula id="IEq4"><alternatives><tex-math id="M6">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${AUC}_{0-30}^{plasma}$$\end{document}</tex-math><inline-graphic xlink:href="11011_2024_1486_Article_IEq4.gif"/></alternatives></inline-formula> values for the two surgical groups (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d). Additionally, the corresponding plots based on the blood concentrations of [<sup>13</sup>C]sucrose are also presented in the Supplementary Data (Fig. <xref rid="MOESM1" ref-type="media">S1</xref>). The blood data (Fig. <xref rid="MOESM1" ref-type="media">S1</xref>) were consistent with the patterns observed with the plasma data (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>), indicating no significant differences between the <inline-formula id="IEq5"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${AUC}_{0-30}^{blood}$$\end{document}</tex-math><inline-graphic xlink:href="11011_2024_1486_Article_IEq5.gif"/></alternatives></inline-formula> values for the two surgical groups (Fig. <xref rid="MOESM1" ref-type="media">S1</xref>d). Neither the surgery (BDL and Sham) nor the time of the study affected the <inline-formula id="IEq6"><alternatives><tex-math id="M8">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${AUC}_{0-30}^{blood}:{AUC}_{0-30}^{plasma}$$\end{document}</tex-math><inline-graphic xlink:href="11011_2024_1486_Article_IEq6.gif"/></alternatives></inline-formula> ratios, which remained constant at 0.55&#x02013;0.58 across all the groups. These AUC ratios are suggestive of hematocrit values of 0.42&#x02013;0.45, considering that sucrose does not distribute to red blood cells.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Plasma concentration-time courses (<bold>a</bold>-<bold>c</bold>) and AUC values (<bold>d</bold>) of [<sup>13</sup>C]sucrose in the bile-duct ligated (BDL) and sham-operated (Sham) animals. Animals were subjected to the BDL or sham surgery. Five days (<bold>a</bold>), two weeks (<bold>b</bold>), or four weeks (<bold>c</bold>) after the surgery, a single intravenous dose of [<sup>13</sup>C]sucrose (10/mg/kg) was administered to different groups (<italic>n</italic>&#x02009;=&#x02009;6&#x02013;7/group) of animals, and the plasma [<sup>13</sup>C]sucrose concentrations were measured. For the plasma concentration-time courses (<bold>a</bold>-<bold>c</bold>), symbols and bars represent the mean and SD, respectively. For the plasma AUC values, symbols and horizontal lines represent individual and mean values, respectively. Statistical significance (ns, not significant) is based on two-way ANOVA, followed by Bonferroni multiple comparisons of the means</p></caption><graphic xlink:href="11011_2024_1486_Fig3_HTML" id="MO3"/></fig></p><p id="Par19">The brain concentrations and uptake clearance (<italic>K</italic><sub><italic>in-plasma</italic></sub>) values of [<sup>13</sup>C]sucrose are presented in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>. BDL did not significantly affect the brain concentrations (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a) or the <italic>K</italic><sub><italic>in-plasma</italic></sub> values (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b) of [<sup>13</sup>C]sucrose at any of the studied time points. As expected, the brain concentrations of [<sup>13</sup>C]sucrose (ng/g range) were negligible (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a) relative to the substantially higher concentrations of the marker in the plasma (&#x000b5;g/mL range) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a-c). Similarly, the <italic>K</italic><sub><italic>in-plasma</italic></sub> values of [<sup>13</sup>C]sucrose in both BDL and Sham animals were very low (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b). Analysis of the relationship between the brain concentration or <italic>K</italic><sub><italic>in-plasma</italic></sub> values of [<sup>13</sup>C]sucrose and the serum biochemical markers revealed a significant relationship only with the serum TBA concentrations in the BDL animals (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). With an increase in the serum TBA concentrations, there was a decline in both the brain concentrations (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a) and <italic>K</italic><sub><italic>in-plasma</italic></sub> values (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b) of [<sup>13</sup>C]sucrose. Similar results were found when the blood, instead of serum, <italic>K</italic><sub><italic>in</italic></sub> values (<italic>K</italic><sub><italic>in-blood</italic></sub>) were compared across different groups (Fig. <xref rid="MOESM1" ref-type="media">S2</xref>a) or were analyzed against the serum TBA concentrations (Fig. <xref rid="MOESM1" ref-type="media">S2</xref>b).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Terminal brain concentrations (<bold>a</bold>) and brain uptake clearance (<italic>K</italic><sub><italic>in-plasma</italic></sub>) values (<bold>b</bold>) of [<sup>13</sup>C]sucrose in the bile-duct ligated (BDL) and sham-operated (Sham) animals. Animals were subjected to the BDL or sham surgery. Five days (<bold>a</bold>), two weeks (<bold>b</bold>), or four weeks (<bold>c</bold>) after the surgery, a single intravenous dose of [<sup>13</sup>C]sucrose (10/mg/kg) was administered to different groups (<italic>n</italic>&#x02009;=&#x02009;6&#x02013;7/group) of animals, and terminal (30&#x000a0;min) brain samples were collected. Symbols and horizontal lines represent individual and mean values, respectively. Statistical significance (ns, not significant) is based on two-way ANOVA, followed by Bonferroni multiple comparisons of the means</p></caption><graphic xlink:href="11011_2024_1486_Fig4_HTML" id="MO4"/></fig><fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>The relationship between the terminal brain concentration (<bold>a</bold>) or brain uptake clearance (<bold>b</bold>) of [<sup>13</sup>C]sucrose and plasma total bile acid concentrations in bile-duct ligated (BDL) animals. The analysis includes all the BDL animals studied five days, two weeks, or four weeks after the surgery (<italic>n</italic>&#x02009;=&#x02009;6&#x02013;7/group). Symbols and lines represent individual animals and the regression line, respectively. Statistical significance is based on linear regression analysis</p></caption><graphic xlink:href="11011_2024_1486_Fig5_HTML" id="MO5"/></fig></p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par20">The normal BBB consists of tight junctions that strictly prevent the paracellular passage of small and large molecules and ions (Daneman and Prat <xref ref-type="bibr" rid="CR16">2015</xref>). However, under different pathophysiologic conditions, the integrity of BBB may be compromised, leading to the passage of endogenous and exogenous compounds and toxins and potential CNS adverse events. Liver diseases are associated with pathophysiological changes that increase the circulating concentrations of neuroinflammatory and neurotoxic compounds such as ammonia, bilirubin, lipopolysaccharides, and cytokines (Butterworth <xref ref-type="bibr" rid="CR6">2013</xref>; Claeys et al. <xref ref-type="bibr" rid="CR14">2021</xref>; Ott and Vilstrup <xref ref-type="bibr" rid="CR46">2014</xref>; Tranah et al. <xref ref-type="bibr" rid="CR57">2013</xref>). Therefore, there is a significant interest in the effects of liver diseases on the BBB barrier permeability (Butterworth <xref ref-type="bibr" rid="CR7">2016</xref>; Chastre et al. <xref ref-type="bibr" rid="CR10">2013</xref>; Cui et al. <xref ref-type="bibr" rid="CR15">2013</xref>; Nguyen <xref ref-type="bibr" rid="CR42">2012</xref>; Wang et al. <xref ref-type="bibr" rid="CR60">2011</xref>; Zaki et al. <xref ref-type="bibr" rid="CR65">1984</xref>). In the current study, we used sucrose as a BBB permeability marker in BDL rats to investigate the effects of cholestatic liver disease on BBB. Our results clearly show that the BBB permeability to sucrose, measured by the brain uptake clearance of the marker, remains unchanged at five days, two weeks, and four weeks after the surgery (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c).</p><p id="Par21">Other studies have reported increased (Dhanda and Sandhir <xref ref-type="bibr" rid="CR20">2017</xref>; Quinn et al. <xref ref-type="bibr" rid="CR50">2014</xref>), no change (Bosoi et al. <xref ref-type="bibr" rid="CR5">2012</xref>; Xu et al. <xref ref-type="bibr" rid="CR64">2016</xref>), or decreased (Wahler et al. <xref ref-type="bibr" rid="CR59">1993</xref>) BBB permeability in BDL rats. Most of these studies (Bosoi et al. <xref ref-type="bibr" rid="CR5">2012</xref>; Dhanda and Sandhir <xref ref-type="bibr" rid="CR20">2017</xref>; Quinn et al. <xref ref-type="bibr" rid="CR50">2014</xref>; Xu et al. <xref ref-type="bibr" rid="CR64">2016</xref>) used EB and/or FL as markers of BBB permeability. Although EB and FL are the top two most widely used markers in BBB permeability literature (Saunders et al. <xref ref-type="bibr" rid="CR51">2015</xref>), their use is associated with some methodological problems, which may be responsible, at least in part, for some of the observed discrepancies in the literature.</p><p id="Par22">The use of EB (MW, 961) as a BBB marker is based on the assumption that after in vivo administration, the dye is completely bound to albumin, and EB-albumin cannot cross the intact BBB. However, it has long been reported (Allen and Orahovats <xref ref-type="bibr" rid="CR1">1950</xref>) that the binding of EB to albumin depends on the EB: albumin molar ratio. Indeed, in vivo doses routinely used in rodents produce measurable free EB concentrations in the plasma (Moos and Mollgard <xref ref-type="bibr" rid="CR39">1993</xref>). Additionally, EB's stability seems to depend on the injection vehicle (Saunders et al. <xref ref-type="bibr" rid="CR51">2015</xref>). Therefore, the use of EB as a marker of BBB permeability has been seriously questioned (Saunders et al. <xref ref-type="bibr" rid="CR51">2015</xref>). Using EB as a marker, Bosoi et al. (<xref ref-type="bibr" rid="CR5">2012</xref>) reported no change in the BBB permeability six weeks after BDL surgery in rats. Similarly, Xu et al. (<xref ref-type="bibr" rid="CR64">2016</xref>) showed no change in the BBB permeability to EB one or two weeks after the BDL surgery in rats. In contrast, increases in BBB permeability to EB in BDL rats have been reported five days (Quinn et al. <xref ref-type="bibr" rid="CR50">2014</xref>) or four weeks (Dhanda and Sandhir <xref ref-type="bibr" rid="CR20">2017</xref>) after the surgery. It is conceivable that these discrepancies might be due, at least in part, to confounding factors affecting the free fraction of the marker in plasma and its associated brain concentrations.</p><p id="Par23">Sodium fluorescein is the most widely used small MW marker for BBB permeability studies in the literature (Saunders et al. <xref ref-type="bibr" rid="CR51">2015</xref>). Most investigators simply measure the concentrations of FL in the brain sometime after the in vivo administration of the marker as a measure of BBB permeability. Similar methods were also used to determine BBB permeability changes in BDL rats after the injection of FL, where both an increase (Dhanda and Sandhir <xref ref-type="bibr" rid="CR20">2017</xref>) and no change (Bosoi et al. <xref ref-type="bibr" rid="CR5">2012</xref>) were reported. We have previously shown that brain concentrations of FL were significantly increased after hepatectomy or hepatic ischemia-reperfusion injury (Miah et al. <xref ref-type="bibr" rid="CR35">2015</xref>). However, both free fraction of the marker in the plasma and free plasma AUC were also higher in the experimental groups than in control animals. When the brain concentrations were corrected for the plasma AUC of the unbound marker (i.e., free <italic>K</italic><sub><italic>in</italic></sub>), there was no change in the BBB permeability to FL (Miah et al. <xref ref-type="bibr" rid="CR35">2015</xref>). Therefore, for accurate measurement of BBB permeability to FL, both its plasma free fraction and AUC should be used to correct the brain concentrations of the marker.</p><p id="Par24">An ideal small MW marker for testing the integrity of the BBB tight junctions is expected to be polar (i.e., no transcellular transport), not bound to plasma proteins, and devoid of influx and efflux transporters at the BBB. Radioactive (<sup>14</sup>C) sucrose has been used as such a marker for more than half a century (Ferguson and Woodbury <xref ref-type="bibr" rid="CR23">1969</xref>). However, the use of radioactive sucrose is confounded by the presence of lipophilic impurities, which disproportionately accumulate in the brain, resulting in a 6-7-fold overestimation of true sucrose <italic>K</italic><sub><italic>in</italic></sub> (Miah et al. <xref ref-type="bibr" rid="CR38">2017b</xref>) and potentially inaccurate conclusions in the effects of pathophysiological conditions on the BBB permeability to sucrose (Miah et al. <xref ref-type="bibr" rid="CR37">2017a</xref>). Our data demonstrating that BDL in rats does not affect the BBB permeability (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c) is based on the estimation of <italic>K</italic><sub><italic>in</italic></sub> of the isotope-labeled [<sup>13</sup>C]sucrose measured by the specific LC-MS/MS analysis (Miah et al. <xref ref-type="bibr" rid="CR36">2016</xref>), which is devoid of the potential methodological problems associated with [<sup>14</sup>C]sucrose and other low MW markers used in the BBB literature.</p><p id="Par25">In addition to the most widely used small MW markers FL (MW, 376&#x000a0;Da) and sucrose (MW, 342&#x000a0;Da), mannitol with a MW of around half the MW of sucrose (182&#x000a0;Da) has also been used as a BBB permeability marker representing small molecules. In a recent study investigating the effects of anesthesia on BBB permeability (Noorani et al. <xref ref-type="bibr" rid="CR44">2023</xref>), we showed that although the absolute permeability of mannitol was about 2-fold higher than sucrose, the magnitude of the BBB opening under isoflurane/sevoflurane was the same for both sucrose and mannitol. Therefore, we expect that any small passive permeability marker in the low MW range&#x02009;&#x0003e;&#x02009;180&#x000a0;Da would behave similarly to sucrose in BDL rats. For any small molecule toxin with more lipophilic character (subject to transcellular transport), potential changes in paracellular permeability are irrelevant.</p><p id="Par26">Another potential area responsible for the discrepancy in the BBB permeability changes in liver diseases might be the correction method for the contaminating blood in the brain vasculature. A popular method is to wash out the blood in the brain vasculature using a physiological perfusate. However, depending on the rate and length of the perfusion, varying degrees of residual blood might be left in the brain tissue, which may affect the measured brain concentrations of the marker. One of the studies that reported no change in the BBB permeability to EB in BDL rats (Xu et al. <xref ref-type="bibr" rid="CR64">2016</xref>) perfused the animals with physiologic saline through the left ventricle until colorless perfusion fluid returned to the right atrium. However, the details of the perfusion, such as its rate and length, were not reported in other studies (Bosoi et al. <xref ref-type="bibr" rid="CR5">2012</xref>; Dhanda and Sandhir <xref ref-type="bibr" rid="CR20">2017</xref>; Quinn et al. <xref ref-type="bibr" rid="CR50">2014</xref>). The contribution of residual blood to total brain concentrations especially becomes significant after high doses and/or shorter times of marker circulation.</p><p id="Par27">We selected a time course of five days to 4&#x000a0;weeks for our studies because the studies reporting an elevated BBB permeability were carried out between five days (Quinn et al. <xref ref-type="bibr" rid="CR50">2014</xref>) and four weeks (Dhanda and Sandhir <xref ref-type="bibr" rid="CR20">2017</xref>) after BDL surgery in rats. Additionally, a report (Kountouras et al. <xref ref-type="bibr" rid="CR30">1984</xref>) investigating the characteristics of the BDL model in Sprague-Dawley rats indicated that the ligation of the bile duct for 15&#x000a0;days or more resulted in fibrosis, with the majority of animals showing cirrhosis at four weeks.</p><p id="Par28">The BDL model was based on double ligation plus bile duct sectioning between the two ligatures (Klein et al. <xref ref-type="bibr" rid="CR29">2017</xref>) to avoid potential bile duct re-epithelization and restoration of the bile flow. The success of the bile duct ligation was confirmed for each animal at the end of the study by laparotomy and visual inspection of the abdominal area, including the presence of a significant dilation of the bile duct anterior to the ligation, before collection of the liver for P450 studies.</p><p id="Par29">The biochemical changes in the plasma of BDL rats observed in our study (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) are consistent with the development of cholestasis reported in other studies in these animals (Bosoi et al. <xref ref-type="bibr" rid="CR5">2012</xref>; Dhanda and Sandhir <xref ref-type="bibr" rid="CR20">2017</xref>; Quinn et al. <xref ref-type="bibr" rid="CR50">2014</xref>; Xu et al. <xref ref-type="bibr" rid="CR64">2016</xref>). In terms of absolute plasma concentrations, our biochemical data in the Sham and BDL rats are within the range of previously reported values for bilirubin (Kountouras et al. <xref ref-type="bibr" rid="CR30">1984</xref>; Xu et al. <xref ref-type="bibr" rid="CR64">2016</xref>), total bile acids (Quinn et al. <xref ref-type="bibr" rid="CR50">2014</xref>; Xu et al. <xref ref-type="bibr" rid="CR64">2016</xref>), and cholesterol (Kinugasa et al. <xref ref-type="bibr" rid="CR28">1981</xref>). The absolute concentrations of ammonia in our studies (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c) were higher than those previously reported in these animals (Espiritu-Ramirez et al. <xref ref-type="bibr" rid="CR22">2018</xref>; Tripathi et al. <xref ref-type="bibr" rid="CR58">2018</xref>), which might be due to in vitro generation of ammonia during the processing of plasma samples (Howanitz et al. <xref ref-type="bibr" rid="CR26">1984</xref>). Nevertheless, a potential overestimation of the absolute plasma concentrations of ammonia does not change the significant differences between the BDL and sham animals observed in our study (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c).</p><p id="Par30">Among the studied biomarkers, ANOVA revealed a significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) effect of time after surgery on the TBA concentrations. Although the plasma TBA concentrations in BDL rats were significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) higher than their corresponding Sham counterparts at all the time points, there was a decrease in the concentrations of TBA in the BDL rats at later times (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b). Similar trends have also been observed in other studies (Quinn et al. <xref ref-type="bibr" rid="CR50">2014</xref>; Xu et al. <xref ref-type="bibr" rid="CR64">2016</xref>), indicating that TBA concentrations peak early after the surgery.</p><p id="Par31">The significant negative correlation between brain concentrations or <italic>K</italic><sub><italic>in</italic></sub> values of [<sup>13</sup>C]sucrose and TBA concentrations in the serum, observed in our studies (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref> and <xref rid="MOESM1" ref-type="media">S2</xref>b), suggests some protective effects of TBA on BBB. Earlier in vivo studies in rats using bile salts sodium dehydrocholate (Spigelman et al. <xref ref-type="bibr" rid="CR53">1983</xref>) or sodium deoxycholate (Greenwood et al. <xref ref-type="bibr" rid="CR24">1991</xref>) showed disruption of BBB and increased permeability of BBB markers after the injection of the bile salts. However, both studies used very high concentrations of bile salts. The study by Spigelman et al. (<xref ref-type="bibr" rid="CR53">1983</xref>) showed consistent BBB disruption in all animals after injection of 1&#x000a0;mL solutions of 15% and 17.5% sodium dehydrocholate into the animals' carotid artery. These doses were also associated with significant toxicity, with most animals showing respiratory depression and convulsion soon after the injection, in addition to 16% mortality. Similarly, using an in situ rat brain perfusion model, Greenwood et al. (<xref ref-type="bibr" rid="CR24">1991</xref>) reported disruption of BBB at very high perfusate concentrations of 1&#x02013;1.5&#x000a0;mM of sodium deoxycholate. They attributed the BBB disruption to the lytic action of the bile acid, which was related to its detergent properties at high concentrations.</p><p id="Par32">Other investigators have reported that the effects of bile acids on the BBB are more complex as they are dependent on both the concentrations (Greenwood et al. <xref ref-type="bibr" rid="CR24">1991</xref>) and degree of hydrophilicity (Palmela et al. <xref ref-type="bibr" rid="CR48">2015</xref>; Xing et al. <xref ref-type="bibr" rid="CR63">2023</xref>) of the bile salts. For example, whereas abnormally high concentrations (1&#x02013;2&#x000a0;mM) of the hydrophobic bile salt deoxycholate damaged BBB, at lower concentrations (0.2&#x000a0;mM) of deoxycholate, BBB remained intact (Greenwood et al. <xref ref-type="bibr" rid="CR24">1991</xref>). Additionally, more recent investigations using in vitro models report a BBB protective effect for hydrophilic bile acids, such as ursodeoxycholic acid (UDCA) (Palmela et al. <xref ref-type="bibr" rid="CR48">2015</xref>). The latter study showed that UDCA prevents or restores the loss of BBB integrity induced by unconjugated bilirubin in monolayers of human brain microvascular endothelial cells. Additionally, a recent review (Xing et al. <xref ref-type="bibr" rid="CR63">2023</xref>) indicated that hydrophilic bile acids such as UDCA and its taurine conjugate have neuroprotective, anti-neuroinflammatory, anti-apoptotic, and antioxidative effects, which protect the BBB integrity. We are unaware of any in vivo investigation of the protective effects of bile salts on the BBB structure or permeability. However, our in vivo results, showing an association between a reduction in the <italic>K</italic><sub><italic>in</italic></sub> values and an increase in the TBA concentrations in the BDL group (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b and Fig. <xref rid="MOESM1" ref-type="media">S2</xref>b), agree with the protective effects of some bile acids reported using the in vitro models (Palmela et al. <xref ref-type="bibr" rid="CR48">2015</xref>). Further studies are needed to confirm the potential protective effects of bile acids on BBB integrity and their mechanisms using both in vitro and in vivo models.</p><p id="Par33">In addition to the effects of BDL on the BBB permeability to sucrose, we also studied the changes in the P450-mediated metabolism in these animals. A potential change in the metabolism of xenobiotics in BDL animals is an important consideration when the BBB marker is subject to metabolism. In those cases, any changes in the brain concentrations of the marker, without correction for changes in its plasma concentrations, may not be indicative of changes in the BBB permeability. In the case of sucrose, any changes in the P450-mediated drug metabolism are not expected to affect the pharmacokinetics of the marker. Although it is well known that sucrose is metabolized in the gastrointestinal tract to glucose and fructose before absorption, intravenously administered sucrose is metabolically stable and is eliminated only by renal clearance of the unchanged marker (Deane et al. <xref ref-type="bibr" rid="CR17">1951</xref>).</p><p id="Par34">The 60%-70% decline in the total P450 contents of the liver five days to four weeks after the BDL surgery (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a) is in agreement with previous studies, which showed a 50% (Mackinnon and Simon <xref ref-type="bibr" rid="CR33">1974</xref>) or a 44% (Chen et al. <xref ref-type="bibr" rid="CR11">1995</xref>) decline, three or five days, respectively, after the BDL surgery in rats. Although not investigated in our current study, the effects of BDL on P450 enzymes are isoenzyme-specific with regard to both protein contents and activity (Kawase et al. <xref ref-type="bibr" rid="CR27">2019</xref>; Tateishi et al. <xref ref-type="bibr" rid="CR56">1998</xref>). Similarly, the 46% reduction in the CPR activity observed in our 5-day BDL animals (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b) is almost identical to the 43% reduction reported in BDL rats five days after the surgery (Chen et al. <xref ref-type="bibr" rid="CR11">1995</xref>). Lastly, the 61%-68% decrease in the activity of ECOD in BDL rats (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c) is in agreement with similar reductions in the total P450 content (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a) and CPR activities (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). Overall, our data confirm previous reports that BDL in rats causes a substantial decline in the total P450 content and enzymatic activity.</p><p id="Par35">Our previous study (Miah et al. <xref ref-type="bibr" rid="CR37">2017a</xref>) showed that using plasma or blood AUC to estimate <italic>K</italic><sub><italic>in</italic></sub> may result in different conclusions for disease-induced changes in BBB permeability to radioactive (<sup>14</sup>C) sucrose. Whereas the <italic>K</italic><sub><italic>in</italic></sub> values calculated based on the blood AUC showed a significant increase because of liver ischemia-reperfusion injury, when the <italic>K</italic><sub><italic>in</italic></sub> was estimated based on the plasma AUC, there was no difference in <italic>K</italic><sub><italic>in</italic></sub> between the sham and experimental groups. These discrepancies were attributed to small lipophilic impurities in [<sup>14</sup>C]sucrose. As opposed to [<sup>14</sup>C]sucrose, when [<sup>13</sup>C]sucrose was used, <italic>K</italic><sub><italic>in-Blood</italic></sub> or <italic>K</italic><sub><italic>in-Plasma</italic></sub> resulted in the same conclusion that the liver ischemia-reperfusion injury did not significantly affect the BBB permeability (Miah et al. <xref ref-type="bibr" rid="CR37">2017a</xref>). Our studies reported here (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b and Fig. <xref rid="MOESM1" ref-type="media">S2</xref>a) confirm that when [<sup>13</sup>C]sucrose is used, the measurement of the marker in blood or serum does not affect the study's outcome. Therefore, when using [<sup>13</sup>C]sucrose as a marker, investigators may quantitate the marker in either plasma or blood.</p><p id="Par36">There was no difference between the Sham and BDL animals in their plasma (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d) or blood (Fig. <xref rid="MOESM1" ref-type="media">S1</xref>d) AUCs of [<sup>13</sup>C]sucrose. Because sucrose is not metabolized by the liver and is eliminated only through the kidneys by glomerular filtration, this suggests no change in the glomerular filtration in BDL rats.</p><p id="Par37">It has been reported that the mean arterial blood pressure is reduced in BDL rats (Bomzon et al. <xref ref-type="bibr" rid="CR4">1990</xref>). Therefore, it may be argued that the delivery of [<sup>13</sup>C]sucrose in BDL rats is slower than the normotensive Sham animals. However, because of its extremely low permeability, BBB uptake clearance of sucrose is not flow-limited. Therefore, any potential change in the brain blood flow is not expected to affect the brain uptake clearance of sucrose.</p><p id="Par38">One of the serious extrahepatic consequences of liver diseases is hepatic encephalopathy, which is a neurological complication manifesting itself as cognitive, psychiatric, and neurological disturbances ranging from mild symptoms to coma (Claeys et al. <xref ref-type="bibr" rid="CR14">2021</xref>; DeMorrow <xref ref-type="bibr" rid="CR18">2019</xref>). Bile duct ligated rats are an animal model of type C hepatic encephalopathy, which is associated with chronic liver diseases (DeMorrow et al. <xref ref-type="bibr" rid="CR19">2021</xref>). Although we did not conduct behavioral tests in our current study, several studies reviewed by DeMorrow et al. (<xref ref-type="bibr" rid="CR19">2021</xref>) indicate that BDL rats develop signs of motor and learning deficits. However, the relationship between hepatic encephalopathy and changes in BBB permeability is not clear, as it is suggested that hepatic encephalopathy might occur in the absence of any BBB permeability changes (Butterworth <xref ref-type="bibr" rid="CR6">2013</xref>; Claeys et al. <xref ref-type="bibr" rid="CR14">2021</xref>).</p><p id="Par39">Our study has a few limitations. For the plasma biomarkers, we focused on confirming the cholestasis in the BDL animals by measurement of bilirubin, total bile acids, and ammonia (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). However, previous studies (Kountouras et al. <xref ref-type="bibr" rid="CR30">1984</xref>; Wu et al. <xref ref-type="bibr" rid="CR62">2018</xref>; Xu et al. <xref ref-type="bibr" rid="CR64">2016</xref>) have clearly shown that the BDL model also leads to liver injury, which manifests itself in increases the liver enzymes, such as aspartate (AST) and alanine (ALT) aminotransferases, and liver tissue histological abnormalities. During the review process, the authors were asked to conduct additional experiments to measure the plasma levels of AST and ALT and to provide a histological analysis of the liver structure to confirm the success of the bile duct ligation model for up to 4&#x000a0;weeks. We were not able to conduct these additional experiments because our plasma and liver samples were exhausted or deteriorated. Despite these limitations, the 40-fold higher (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) levels of bilirubin (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a), 10-fold (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) higher levels of total bile acids (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b), and 60% reduction (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) in the liver total P450 content (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a) in BDL rats at 4&#x000a0;weeks coupled with the visual confirmation of the bile duct dilation at the end of the experiments are all suggestive of the success and preservation of bile duct ligation in our experiments.</p><p id="Par40">Another study limitation is that we did not study the BBB structure, including tight junctions, using electron microscopy. However, previous studies (Nguyen et al. <xref ref-type="bibr" rid="CR43">2006</xref>; Nguyen <xref ref-type="bibr" rid="CR41">2010</xref>) in an acute liver failure model have shown an intact BBB structure with normal tight junctions even in the presence of an increased BBB permeability, measured by Evans blue. Therefore, a disruption of BBB integrity in our BDL model, which is less severe than acute liver failure, in the absence of any changes in the BBB permeability to sucrose is unlikely.</p></sec><sec id="Sec16"><title>Conclusions</title><p id="Par41">In conclusion, the BBB permeability to the hydrophilic marker [<sup>13</sup>C]sucrose remained unchanged in bile duct-ligated rats up to four weeks after the surgery. This conclusion is based on the calculation of brain uptake clearance of the marker, which utilizes both the marker's brain and plasma (or blood) concentrations quantitated using a specific LC-MS/MS method.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11011_2024_1486_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 547 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank Jennifer H. Phan and Dr. Barent N. DuBois from Chapman University School of Pharmacy for assistance with the cytochrome P450 studies.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>Reza Mehvar, Ulrich Bickel, and Mohammad K. Miah designed the experiments and analyzed the data; Mohammad K. Miah performed the experiments; Reza Mehvar wrote the first draft of the manuscript; all authors revised the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by SCELC, Statewide California Electronic Library Consortium</p><p>Financial support for this study was provided by the Chapman University School of Pharmacy and the Center for Blood&#x02013;Brain Barrier Research at Texas Tech School of Pharmacy.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>Except for the plasma or blood concentrations, all individual data are provided for each animal in this manuscript. Individual plasma or blood concentration-time data will be provided upon request from the corresponding author.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval</title><p id="Par42">All the animal procedures used in this study were approved by Texas Tech University Health Sciences Center&#x02019;s Institutional Animal Care and Use Committee and were consistent with the guidelines set by the National Research Council (USA) Committee for the Update of the Guide for the Care and Use of Laboratory Animals (8th edition, 2011).</p></notes><notes id="FPar2"><title>Consent to participate</title><p id="Par43">Not applicable.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par44">All authors have read and approved the manuscript.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par45">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>TH</given-names></name><name><surname>Orahovats</surname><given-names>PD</given-names></name></person-group><article-title>Combination of toluidine dye isomers with plasma albumin</article-title><source>Am J Physiol</source><year>1950</year><volume>161</volume><fpage>473</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1152/ajplegacy.1950.161.3.473</pub-id><pub-id pub-id-type="pmid">15432649</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Allen TH, Orahovats PD (1950) Combination of toluidine dye isomers with plasma albumin. Am J Physiol 161:473&#x02013;482<pub-id pub-id-type="pmid">15432649</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Alqahtani</surname><given-names>F</given-names></name><name><surname>Chowdhury</surname><given-names>EA</given-names></name><name><surname>Bhattacharya</surname><given-names>R</given-names></name><name><surname>Noorani</surname><given-names>B</given-names></name><name><surname>Mehvar</surname><given-names>R</given-names></name><name><surname>Bickel</surname><given-names>U</given-names></name></person-group><article-title>Brain uptake of [<sup>13</sup>C] and [<sup>14</sup>C]sucrose quantified by microdialysis and whole tissue analysis in mice</article-title><source>Drug Metab Dispos</source><year>2018</year><volume>46</volume><fpage>1514</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1124/dmd.118.082909</pub-id><pub-id pub-id-type="pmid">30115645</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Alqahtani F, Chowdhury EA, Bhattacharya R, Noorani B, Mehvar R, Bickel U (2018) Brain uptake of [<sup>13</sup>C] and [<sup>14</sup>C]sucrose quantified by microdialysis and whole tissue analysis in mice. Drug Metab Dispos 46:1514&#x02013;1518<pub-id pub-id-type="pmid">30115645</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Bickel</surname><given-names>U</given-names></name></person-group><article-title>Modeling blood-brain barrier permeability to solutes and drugs in vivo</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><fpage>1696</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14081696</pub-id><pub-id pub-id-type="pmid">36015323</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Bickel U (2022) Modeling blood-brain barrier permeability to solutes and drugs in vivo. Pharmaceutics 14:1696<pub-id pub-id-type="pmid">36015323</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Bomzon</surname><given-names>A</given-names></name><name><surname>Weinbroum</surname><given-names>A</given-names></name><name><surname>Kamenetz</surname><given-names>L</given-names></name></person-group><article-title>Systemic hypotension and pressor responsiveness in cholestasis. A study in conscious 3-day bile duct ligated rats</article-title><source>J Hepatol</source><year>1990</year><volume>11</volume><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/0168-8278(90)90274-U</pub-id><pub-id pub-id-type="pmid">2398269</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Bomzon A, Weinbroum A, Kamenetz L (1990) Systemic hypotension and pressor responsiveness in cholestasis. A study in conscious 3-day bile duct ligated rats. J Hepatol 11:70&#x02013;76<pub-id pub-id-type="pmid">2398269</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Bosoi</surname><given-names>CR</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Huynh</surname><given-names>J</given-names></name><name><surname>Parent-Robitaille</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Tremblay</surname><given-names>M</given-names></name><name><surname>Rose</surname><given-names>CF</given-names></name></person-group><article-title>Systemic oxidative stress is implicated in the pathogenesis of brain edema in rats with chronic liver failure</article-title><source>Free Radic Biol Med</source><year>2012</year><volume>52</volume><fpage>1228</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.01.006</pub-id><pub-id pub-id-type="pmid">22300646</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Bosoi CR, Yang X, Huynh J, Parent-Robitaille C, Jiang W, Tremblay M, Rose CF (2012) Systemic oxidative stress is implicated in the pathogenesis of brain edema in rats with chronic liver failure. Free Radic Biol Med 52:1228&#x02013;1235<pub-id pub-id-type="pmid">22300646</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Butterworth</surname><given-names>RF</given-names></name></person-group><article-title>The liver-brain axis in liver failure: neuroinflammation and encephalopathy</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2013</year><volume>10</volume><fpage>522</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2013.99</pub-id><pub-id pub-id-type="pmid">23817325</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Butterworth RF (2013) The liver-brain axis in liver failure: neuroinflammation and encephalopathy. Nat Rev Gastroenterol Hepatol 10:522&#x02013;528<pub-id pub-id-type="pmid">23817325</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Butterworth</surname><given-names>RF</given-names></name></person-group><article-title>The concept of "the inflamed brain" in acute liver failure: mechanisms and new therapeutic opportunities</article-title><source>Metab Brain Dis</source><year>2016</year><volume>31</volume><fpage>1283</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.1007/s11011-015-9747-0</pub-id><pub-id pub-id-type="pmid">26481639</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Butterworth RF (2016) The concept of &#x0201c;the inflamed brain&#x0201d; in acute liver failure: mechanisms and new therapeutic opportunities. Metab Brain Dis 31:1283&#x02013;1287<pub-id pub-id-type="pmid">26481639</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Cauli</surname><given-names>O</given-names></name><name><surname>Lopez-Larrubia</surname><given-names>P</given-names></name><name><surname>Rodrigo</surname><given-names>R</given-names></name><name><surname>Agusti</surname><given-names>A</given-names></name><name><surname>Boix</surname><given-names>J</given-names></name><name><surname>Nieto-Charques</surname><given-names>L</given-names></name><name><surname>Cerdan</surname><given-names>S</given-names></name><name><surname>Felipo</surname><given-names>V</given-names></name></person-group><article-title>Brain region-selective mechanisms contribute to the progression of cerebral alterations in acute liver failure in rats</article-title><source>Gastroenterology</source><year>2011</year><volume>140</volume><fpage>638</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2010.10.043</pub-id><pub-id pub-id-type="pmid">20977905</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Cauli O, Lopez-Larrubia P, Rodrigo R, Agusti A, Boix J, Nieto-Charques L, Cerdan S, Felipo V (2011) Brain region-selective mechanisms contribute to the progression of cerebral alterations in acute liver failure in rats. Gastroenterology 140:638&#x02013;645<pub-id pub-id-type="pmid">20977905</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Chandrashekar</surname><given-names>DV</given-names></name><name><surname>DuBois</surname><given-names>BN</given-names></name><name><surname>Rashid</surname><given-names>M</given-names></name><name><surname>Mehvar</surname><given-names>R</given-names></name></person-group><article-title>Effects of chronic cirrhosis induced by intraperitoneal thioacetamide injection on the protein content and Michaelis-Menten kinetics of cytochrome P450 enzymes in the rat liver microsomes</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2023</year><volume>132</volume><fpage>197</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1111/bcpt.13813</pub-id><pub-id pub-id-type="pmid">36370118</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Chandrashekar DV, DuBois BN, Rashid M, Mehvar R (2023) Effects of chronic cirrhosis induced by intraperitoneal thioacetamide injection on the protein content and Michaelis-Menten kinetics of cytochrome P450 enzymes in the rat liver microsomes. Basic Clin Pharmacol Toxicol 132:197&#x02013;210<pub-id pub-id-type="pmid">36370118</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Chastre</surname><given-names>A</given-names></name><name><surname>Belanger</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>BN</given-names></name><name><surname>Butterworth</surname><given-names>RF</given-names></name></person-group><article-title>Lipopolysaccharide precipitates hepatic encephalopathy and increases blood-brain barrier permeability in mice with acute liver failure</article-title><source>Liver Int</source><year>2013</year><volume>34</volume><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1111/liv.12252</pub-id><pub-id pub-id-type="pmid">23910048</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Chastre A, Belanger M, Nguyen BN, Butterworth RF (2013) Lipopolysaccharide precipitates hepatic encephalopathy and increases blood-brain barrier permeability in mice with acute liver failure. Liver Int 34:353&#x02013;361<pub-id pub-id-type="pmid">23910048</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Murray</surname><given-names>M</given-names></name><name><surname>Liddle</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>X-M</given-names></name><name><surname>Farrell</surname><given-names>GC</given-names></name></person-group><article-title>Downregulation of male-specific cytochrome P450s 2C11 and 3A2 in bile duct&#x02013;ligated male rats: importance to reduced hepatic content of cytochrome P450 in cholestasis</article-title><source>Hepatology</source><year>1995</year><volume>22</volume><fpage>580</fpage><lpage>587</lpage><pub-id pub-id-type="pmid">7635428</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Chen J, Murray M, Liddle C, Jiang X-M, Farrell GC (1995) Downregulation of male-specific cytochrome P450s 2C11 and 3A2 in bile duct&#x02013;ligated male rats: importance to reduced hepatic content of cytochrome P450 in cholestasis. Hepatology 22:580&#x02013;587<pub-id pub-id-type="pmid">7635428</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Ohashi</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Eckman</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>JH</given-names></name></person-group><article-title>Disruptions of occludin and claudin-5 in brain endothelial cells in vitro and in brains of mice with acute liver failure</article-title><source>Hepatology</source><year>2009</year><volume>50</volume><fpage>1914</fpage><lpage>1923</lpage><pub-id pub-id-type="doi">10.1002/hep.23203</pub-id><pub-id pub-id-type="pmid">19821483</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Chen F, Ohashi N, Li W, Eckman C, Nguyen JH (2009) Disruptions of occludin and claudin-5 in brain endothelial cells in vitro and in brains of mice with acute liver failure. Hepatology 50:1914&#x02013;1923<pub-id pub-id-type="pmid">19821483</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Radisky</surname><given-names>ES</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Batra</surname><given-names>J</given-names></name><name><surname>Hata</surname><given-names>T</given-names></name><name><surname>Hori</surname><given-names>T</given-names></name><name><surname>Baine</surname><given-names>AM</given-names></name><name><surname>Gardner</surname><given-names>L</given-names></name><name><surname>Yue</surname><given-names>MY</given-names></name><name><surname>Bu</surname><given-names>G</given-names></name><name><surname>Del Zoppo</surname><given-names>G</given-names></name><name><surname>Patel</surname><given-names>TC</given-names></name><name><surname>Nguyen</surname><given-names>JH</given-names></name></person-group><article-title>TIMP-1 attenuates blood-brain barrier permeability in mice with acute liver failure</article-title><source>J Cereb Blood Flow Metab</source><year>2013</year><volume>33</volume><fpage>1041</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2013.45</pub-id><pub-id pub-id-type="pmid">23532086</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Chen F, Radisky ES, Das P, Batra J, Hata T, Hori T, Baine AM, Gardner L, Yue MY, Bu G, Del Zoppo G, Patel TC, Nguyen JH (2013) TIMP-1 attenuates blood-brain barrier permeability in mice with acute liver failure. J Cereb Blood Flow Metab 33:1041&#x02013;1049<pub-id pub-id-type="pmid">23532086</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Claeys</surname><given-names>W</given-names></name><name><surname>Van Hoecke</surname><given-names>L</given-names></name><name><surname>Lefere</surname><given-names>S</given-names></name><name><surname>Geerts</surname><given-names>A</given-names></name><name><surname>Verhelst</surname><given-names>X</given-names></name><name><surname>Van Vlierberghe</surname><given-names>H</given-names></name><name><surname>Degroote</surname><given-names>H</given-names></name><name><surname>Devisscher</surname><given-names>L</given-names></name><name><surname>Vandenbroucke</surname><given-names>RE</given-names></name><name><surname>Van Steenkiste</surname><given-names>C</given-names></name></person-group><article-title>The neurogliovascular unit in hepatic encephalopathy</article-title><source>JHEP Rep</source><year>2021</year><volume>3</volume><fpage>100352</fpage><pub-id pub-id-type="doi">10.1016/j.jhepr.2021.100352</pub-id><pub-id pub-id-type="pmid">34611619</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Claeys W, Van Hoecke L, Lefere S, Geerts A, Verhelst X, Van Vlierberghe H, Degroote H, Devisscher L, Vandenbroucke RE, Van Steenkiste C (2021) The neurogliovascular unit in hepatic encephalopathy. JHEP Rep 3:100352<pub-id pub-id-type="pmid">34611619</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>CM</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name></person-group><article-title>Alterations of blood-brain barrier and associated factors in acute liver failure</article-title><source>Gastroenterol Res Pract</source><year>2013</year><volume>2013</volume><fpage>841707</fpage><pub-id pub-id-type="doi">10.1155/2013/841707</pub-id><pub-id pub-id-type="pmid">23762040</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Cui W, Sun CM, Liu P (2013) Alterations of blood-brain barrier and associated factors in acute liver failure. Gastroenterol Res Pract 2013:841707<pub-id pub-id-type="pmid">23762040</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Daneman</surname><given-names>R</given-names></name><name><surname>Prat</surname><given-names>A</given-names></name></person-group><article-title>The blood-brain barrier</article-title><source>Cold Spring Harb Perspect Biol</source><year>2015</year><volume>7</volume><fpage>a020412</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a020412</pub-id><pub-id pub-id-type="pmid">25561720</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Daneman R, Prat A (2015) The blood-brain barrier. Cold Spring Harb Perspect Biol 7:a020412<pub-id pub-id-type="pmid">25561720</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Deane</surname><given-names>N</given-names></name><name><surname>Schreiner</surname><given-names>GE</given-names></name><name><surname>Robertson</surname><given-names>JS</given-names></name></person-group><article-title>The velocity of distribution of sucrose between plasma and interstitial fluid, with reference to the use of sucrose for the measurement or extracellular fluid in man</article-title><source>J Clin Invest</source><year>1951</year><volume>30</volume><fpage>1463</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1172/JCI102554</pub-id><pub-id pub-id-type="pmid">14897904</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Deane N, Schreiner GE, Robertson JS (1951) The velocity of distribution of sucrose between plasma and interstitial fluid, with reference to the use of sucrose for the measurement or extracellular fluid in man. J Clin Invest 30:1463&#x02013;1468<pub-id pub-id-type="pmid">14897904</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>DeMorrow</surname><given-names>S</given-names></name></person-group><article-title>Bile acids in hepatic encephalopathy</article-title><source>J Clin Exp Hepatol</source><year>2019</year><volume>9</volume><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.jceh.2018.04.011</pub-id><pub-id pub-id-type="pmid">30774268</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">DeMorrow S (2019) Bile acids in hepatic encephalopathy. J Clin Exp Hepatol 9:117&#x02013;124<pub-id pub-id-type="pmid">30774268</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>DeMorrow</surname><given-names>S</given-names></name><name><surname>Cudalbu</surname><given-names>C</given-names></name><name><surname>Davies</surname><given-names>N</given-names></name><name><surname>Jayakumar</surname><given-names>AR</given-names></name><name><surname>Rose</surname><given-names>CF</given-names></name></person-group><article-title>2021 ISHEN guidelines on animal models of hepatic encephalopathy</article-title><source>Liver Int</source><year>2021</year><volume>41</volume><fpage>1474</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1111/liv.14911</pub-id><pub-id pub-id-type="pmid">33900013</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">DeMorrow S, Cudalbu C, Davies N, Jayakumar AR, Rose CF (2021) 2021 ISHEN guidelines on animal models of hepatic encephalopathy. Liver Int 41:1474&#x02013;1488<pub-id pub-id-type="pmid">33900013</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Dhanda</surname><given-names>S</given-names></name><name><surname>Sandhir</surname><given-names>R</given-names></name></person-group><article-title>Blood-brain barrier permeability is exacerbated in experimental model of hepatic encephalopathy via MMP-9 activation and downregulation of tight junction proteins</article-title><source>Mol Neurobiol</source><year>2017</year><volume>55</volume><fpage>3642</fpage><lpage>3659</lpage><pub-id pub-id-type="pmid">28523565</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Dhanda S, Sandhir R (2017) Blood-brain barrier permeability is exacerbated in experimental model of hepatic encephalopathy via MMP-9 activation and downregulation of tight junction proteins. Mol Neurobiol 55:3642&#x02013;3659<pub-id pub-id-type="pmid">28523565</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>D'Mello</surname><given-names>C</given-names></name><name><surname>Swain</surname><given-names>MG</given-names></name></person-group><article-title>Liver-brain inflammation axis</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2011</year><volume>301</volume><fpage>G749</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00184.2011</pub-id><pub-id pub-id-type="pmid">21868631</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">D&#x02019;Mello C, Swain MG (2011) Liver-brain inflammation axis. Am J Physiol Gastrointest Liver Physiol 301:G749-761<pub-id pub-id-type="pmid">21868631</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Espiritu-Ramirez</surname><given-names>P</given-names></name><name><surname>Ortega-Balderas</surname><given-names>NY</given-names></name><name><surname>Sevilla-Tapia</surname><given-names>L</given-names></name><name><surname>Montiel-Martinez</surname><given-names>AG</given-names></name><name><surname>Pastor-Flores</surname><given-names>AR</given-names></name><name><surname>Palomares</surname><given-names>LA</given-names></name><name><surname>Torres-Vega</surname><given-names>MA</given-names></name></person-group><article-title>Gene therapy for treatment of chronic hyperammonemia in a rat model of hepatic encephalopathy</article-title><source>Ann Hepatol</source><year>2018</year><volume>17</volume><fpage>1026</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.5604/01.3001.0012.7203</pub-id><pub-id pub-id-type="pmid">30600292</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Espiritu-Ramirez P, Ortega-Balderas NY, Sevilla-Tapia L, Montiel-Martinez AG, Pastor-Flores AR, Palomares LA, Torres-Vega MA (2018) Gene therapy for treatment of chronic hyperammonemia in a rat model of hepatic encephalopathy. Ann Hepatol 17:1026&#x02013;1034<pub-id pub-id-type="pmid">30600292</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>RK</given-names></name><name><surname>Woodbury</surname><given-names>DM</given-names></name></person-group><article-title>Penetration of <sup>14</sup>C-inulin and <sup>14</sup>C-sucrose into brain, cerebrospinal fluid, and skeletal muscle of developing rats</article-title><source>Exp Brain Res</source><year>1969</year><volume>7</volume><fpage>181</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1007/BF00239028</pub-id><pub-id pub-id-type="pmid">5795246</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Ferguson RK, Woodbury DM (1969) Penetration of <sup>14</sup>C-inulin and <sup>14</sup>C-sucrose into brain, cerebrospinal fluid, and skeletal muscle of developing rats. Exp Brain Res 7:181&#x02013;194<pub-id pub-id-type="pmid">5795246</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwood</surname><given-names>J</given-names></name><name><surname>Adu</surname><given-names>J</given-names></name><name><surname>Davey</surname><given-names>AJ</given-names></name><name><surname>Abbott</surname><given-names>NJ</given-names></name><name><surname>Bradbury</surname><given-names>MW</given-names></name></person-group><article-title>The effect of bile salts on the permeability and ultrastructure of the perfused, energy-depleted, rat blood-brain barrier</article-title><source>J Cereb Blood Flow Metab</source><year>1991</year><volume>11</volume><fpage>644</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.1991.116</pub-id><pub-id pub-id-type="pmid">2050752</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Greenwood J, Adu J, Davey AJ, Abbott NJ, Bradbury MW (1991) The effect of bile salts on the permeability and ultrastructure of the perfused, energy-depleted, rat blood-brain barrier. J Cereb Blood Flow Metab 11:644&#x02013;654<pub-id pub-id-type="pmid">2050752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><mixed-citation publication-type="other">Guengerich FP (1994) Analysis and characterization of enzymes. In:&#x000a0;Hayes AW (ed),&#x000a0;Principles and methods of toxicology, vol. Raven Press, New York, pp 1259&#x02013;1313</mixed-citation></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Howanitz</surname><given-names>JH</given-names></name><name><surname>Howanitz</surname><given-names>PJ</given-names></name><name><surname>Skrodzki</surname><given-names>CA</given-names></name><name><surname>Iwanski</surname><given-names>JA</given-names></name></person-group><article-title>Influences of specimen processing and storage conditions on results for plasma ammonia</article-title><source>Clin Chem</source><year>1984</year><volume>30</volume><fpage>906</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1093/clinchem/30.6.906</pub-id><pub-id pub-id-type="pmid">6723050</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Howanitz JH, Howanitz PJ, Skrodzki CA, Iwanski JA (1984) Influences of specimen processing and storage conditions on results for plasma ammonia. Clin Chem 30:906&#x02013;908<pub-id pub-id-type="pmid">6723050</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Kawase</surname><given-names>A</given-names></name><name><surname>Kazaoka</surname><given-names>A</given-names></name><name><surname>Yamamoto</surname><given-names>R</given-names></name><name><surname>Minakata</surname><given-names>R</given-names></name><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Iwaki</surname><given-names>M</given-names></name></person-group><article-title>Changes in transporters and metabolizing enzymes in the livers of rats with bile duct ligation</article-title><source>J Pharm Pharm Sci</source><year>2019</year><volume>22</volume><fpage>457</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.18433/jpps30637</pub-id><pub-id pub-id-type="pmid">31539322</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Kawase A, Kazaoka A, Yamamoto R, Minakata R, Shimada H, Iwaki M (2019) Changes in transporters and metabolizing enzymes in the livers of rats with bile duct ligation. J Pharm Pharm Sci 22:457&#x02013;465<pub-id pub-id-type="pmid">31539322</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Kinugasa</surname><given-names>T</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Kadowaki</surname><given-names>M</given-names></name><name><surname>Takase</surname><given-names>H</given-names></name><name><surname>Nomura</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name></person-group><article-title>Effect of bile duct ligation on bile acid metabolism in rats</article-title><source>J Lipid Res</source><year>1981</year><volume>22</volume><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/S0022-2275(20)35363-3</pub-id><pub-id pub-id-type="pmid">7240953</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Kinugasa T, Uchida K, Kadowaki M, Takase H, Nomura Y, Saito Y (1981) Effect of bile duct ligation on bile acid metabolism in rats. J Lipid Res 22:201&#x02013;207<pub-id pub-id-type="pmid">7240953</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>S</given-names></name><name><surname>Schierwagen</surname><given-names>R</given-names></name><name><surname>Uschner</surname><given-names>FE</given-names></name><name><surname>Trebicka</surname><given-names>J</given-names></name></person-group><article-title>Mouse and rat models of induction of hepatic fibrosis and assessment of portal hypertension</article-title><source>Methods Mol Biol</source><year>2017</year><volume>1627</volume><fpage>91</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7113-8_7</pub-id><pub-id pub-id-type="pmid">28836197</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Klein S, Schierwagen R, Uschner FE, Trebicka J (2017) Mouse and rat models of induction of hepatic fibrosis and assessment of portal hypertension. Methods Mol Biol 1627:91&#x02013;116<pub-id pub-id-type="pmid">28836197</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Kountouras</surname><given-names>J</given-names></name><name><surname>Billing</surname><given-names>BH</given-names></name><name><surname>Scheuer</surname><given-names>PJ</given-names></name></person-group><article-title>Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat</article-title><source>Br J Exp Pathol</source><year>1984</year><volume>65</volume><fpage>305</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">6743531</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Kountouras J, Billing BH, Scheuer PJ (1984) Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 65:305&#x02013;311<pub-id pub-id-type="pmid">6743531</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><mixed-citation publication-type="other">Lake BG (1987) Preparation and characterisation of microsomal fractions for studies on xenobiotic metabolism. In:&#x000a0;Snell K, Mullock B (eds), Biochemical toxicology, a practical approach, vol. IRL Press, Oxford, pp 183&#x02013;215</mixed-citation></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Weng</surname><given-names>H</given-names></name><name><surname>Hellerbrand</surname><given-names>C</given-names></name><name><surname>ten Dijke</surname><given-names>P</given-names></name><name><surname>Dooley</surname><given-names>S</given-names></name></person-group><article-title>Animal models of chronic liver diseases</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2013</year><volume>304</volume><fpage>G449</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00199.2012</pub-id><pub-id pub-id-type="pmid">23275613</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Liu Y, Meyer C, Xu C, Weng H, Hellerbrand C, ten Dijke P, Dooley S (2013) Animal models of chronic liver diseases. Am J Physiol Gastrointest Liver Physiol 304:G449-468<pub-id pub-id-type="pmid">23275613</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Mackinnon</surname><given-names>AM</given-names></name><name><surname>Simon</surname><given-names>FR</given-names></name></person-group><article-title>Reduced synthesis of hepatic microsomal cytochroma P450 in the bile duct ligated rat</article-title><source>Biochem Biophys Res Commun</source><year>1974</year><volume>56</volume><fpage>437</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/0006-291X(74)90861-4</pub-id><pub-id pub-id-type="pmid">4823875</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Mackinnon AM, Simon FR (1974) Reduced synthesis of hepatic microsomal cytochroma P450 in the bile duct ligated rat. Biochem Biophys Res Commun 56:437&#x02013;443<pub-id pub-id-type="pmid">4823875</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>McMillin</surname><given-names>MA</given-names></name><name><surname>Frampton</surname><given-names>GA</given-names></name><name><surname>Seiwell</surname><given-names>AP</given-names></name><name><surname>Patel</surname><given-names>NS</given-names></name><name><surname>Jacobs</surname><given-names>AN</given-names></name><name><surname>DeMorrow</surname><given-names>S</given-names></name></person-group><article-title>TGFbeta1 exacerbates blood-brain barrier permeability in a mouse model of hepatic encephalopathy via upregulation of MMP9 and downregulation of claudin-5</article-title><source>Lab Invest</source><year>2015</year><volume>95</volume><fpage>903</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2015.70</pub-id><pub-id pub-id-type="pmid">26006017</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">McMillin MA, Frampton GA, Seiwell AP, Patel NS, Jacobs AN, DeMorrow S (2015) TGFbeta1 exacerbates blood-brain barrier permeability in a mouse model of hepatic encephalopathy via upregulation of MMP9 and downregulation of claudin-5. Lab Invest 95:903&#x02013;913<pub-id pub-id-type="pmid">26006017</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Miah</surname><given-names>MK</given-names></name><name><surname>Shaik</surname><given-names>IH</given-names></name><name><surname>Bickel</surname><given-names>U</given-names></name><name><surname>Mehvar</surname><given-names>R</given-names></name></person-group><article-title>Effects of Pringle maneuver and partial hepatectomy on the pharmacokinetics and blood-brain barrier permeability of sodium fluorescein in rats</article-title><source>Brain Res</source><year>2015</year><volume>1618</volume><fpage>249</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2015.05.038</pub-id><pub-id pub-id-type="pmid">26051428</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Miah MK, Shaik IH, Bickel U, Mehvar R (2015) Effects of Pringle maneuver and partial hepatectomy on the pharmacokinetics and blood-brain barrier permeability of sodium fluorescein in rats. Brain Res 1618:249&#x02013;260<pub-id pub-id-type="pmid">26051428</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Miah</surname><given-names>MK</given-names></name><name><surname>Bickel</surname><given-names>U</given-names></name><name><surname>Mehvar</surname><given-names>R</given-names></name></person-group><article-title>Development and validation of a sensitive UPLC-MS/MS method for the quantitation of [<sup>13</sup>C]sucrose in rat plasma, blood, and brain: Its application to the measurement of blood-brain barrier permeability</article-title><source>J Chromatogr B Analyt Technol Biomed Life Sci</source><year>2016</year><volume>1015</volume><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2016.02.017</pub-id><pub-id pub-id-type="pmid">26919445</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Miah MK, Bickel U, Mehvar R (2016) Development and validation of a sensitive UPLC-MS/MS method for the quantitation of [<sup>13</sup>C]sucrose in rat plasma, blood, and brain: Its application to the measurement of blood-brain barrier permeability. J Chromatogr B Analyt Technol Biomed Life Sci 1015:105&#x02013;110<pub-id pub-id-type="pmid">26919445</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Miah</surname><given-names>MK</given-names></name><name><surname>Bickel</surname><given-names>U</given-names></name><name><surname>Mehvar</surname><given-names>R</given-names></name></person-group><article-title>Effects of hepatic ischemia-reperfusion injury on the blood-brain barrier permeability to [<sup>14</sup>C] and [<sup>13</sup>C]sucrose</article-title><source>Metab Brain Dis</source><year>2017</year><volume>32</volume><fpage>1903</fpage><lpage>1912</lpage><pub-id pub-id-type="doi">10.1007/s11011-017-0069-2</pub-id><pub-id pub-id-type="pmid">28779418</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Miah MK, Bickel U, Mehvar R (2017a) Effects of hepatic ischemia-reperfusion injury on the blood-brain barrier permeability to [<sup>14</sup>C] and [<sup>13</sup>C]sucrose. Metab Brain Dis 32:1903&#x02013;1912<pub-id pub-id-type="pmid">28779418</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Miah</surname><given-names>MK</given-names></name><name><surname>Chowdhury</surname><given-names>EA</given-names></name><name><surname>Bickel</surname><given-names>U</given-names></name><name><surname>Mehvar</surname><given-names>R</given-names></name></person-group><article-title>Evaluation of [<sup>14</sup>C] and [<sup>13</sup>C]sucrose as blood-brain barrier permeability markers</article-title><source>J Pharm Sci</source><year>2017</year><volume>106</volume><fpage>1659</fpage><lpage>1669</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2017.02.011</pub-id><pub-id pub-id-type="pmid">28238901</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Miah MK, Chowdhury EA, Bickel U, Mehvar R (2017b) Evaluation of [<sup>14</sup>C] and [<sup>13</sup>C]sucrose as blood-brain barrier permeability markers. J Pharm Sci 106:1659&#x02013;1669<pub-id pub-id-type="pmid">28238901</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Moos</surname><given-names>T</given-names></name><name><surname>Mollgard</surname><given-names>K</given-names></name></person-group><article-title>Cerebrovascular permeability to azo dyes and plasma proteins in rodents of different ages</article-title><source>Neuropathol Appl Neurobiol</source><year>1993</year><volume>19</volume><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.1993.tb00416.x</pub-id><pub-id pub-id-type="pmid">8316332</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Moos T, Mollgard K (1993) Cerebrovascular permeability to azo dyes and plasma proteins in rodents of different ages. Neuropathol Appl Neurobiol 19:120&#x02013;127<pub-id pub-id-type="pmid">8316332</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><mixed-citation publication-type="other">National Research Council (2011) Guide for the care and use of laboratory animals, 8th edn. Academies Press, Washington, D.C.</mixed-citation></ref><ref id="CR41"><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>JH</given-names></name></person-group><article-title>Subtle BBB alterations in brain edema associated with acute liver failure</article-title><source>Neurochem Int</source><year>2010</year><volume>56</volume><fpage>203</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2009.07.013</pub-id><pub-id pub-id-type="pmid">20201130</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Nguyen JH (2010) Subtle BBB alterations in brain edema associated with acute liver failure. Neurochem Int 56:203&#x02013;204<pub-id pub-id-type="pmid">20201130</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>JH</given-names></name></person-group><article-title>Blood-brain barrier in acute liver failure</article-title><source>Neurochem Int</source><year>2012</year><volume>60</volume><fpage>678</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2011.10.012</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Nguyen JH (2012) Blood-brain barrier in acute liver failure. Neurochem Int 60:678&#x02013;683</mixed-citation></citation-alternatives></ref><ref id="CR43"><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>JH</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Steers</surname><given-names>J</given-names></name><name><surname>Sevlever</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Shimojima</surname><given-names>N</given-names></name><name><surname>Castanedes-Casey</surname><given-names>M</given-names></name><name><surname>Genco</surname><given-names>P</given-names></name><name><surname>Golde</surname><given-names>T</given-names></name><name><surname>Richelson</surname><given-names>E</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>McKinney</surname><given-names>M</given-names></name><name><surname>Eckman</surname><given-names>CB</given-names></name></person-group><article-title>Matrix metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic failure mice</article-title><source>J Hepatol</source><year>2006</year><volume>44</volume><fpage>1105</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2005.09.019</pub-id><pub-id pub-id-type="pmid">16458990</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Nguyen JH, Yamamoto S, Steers J, Sevlever D, Lin W, Shimojima N, Castanedes-Casey M, Genco P, Golde T, Richelson E, Dickson D, McKinney M, Eckman CB (2006) Matrix metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic failure mice. J Hepatol 44:1105&#x02013;1114<pub-id pub-id-type="pmid">16458990</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Noorani</surname><given-names>B</given-names></name><name><surname>Chowdhury</surname><given-names>EA</given-names></name><name><surname>Alqahtani</surname><given-names>F</given-names></name><name><surname>Ahn</surname><given-names>Y</given-names></name><name><surname>Nozohouri</surname><given-names>E</given-names></name><name><surname>Zoubi</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>D</given-names></name><name><surname>Wood</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Siddique</surname><given-names>MB</given-names></name><name><surname>Al-Ahmad</surname><given-names>A</given-names></name><name><surname>Mehvar</surname><given-names>R</given-names></name><name><surname>Bickel</surname><given-names>U</given-names></name></person-group><article-title>Effects of volatile anesthetics versus ketamine on blood-brain barrier permeability via lipid-mediated alterations of endothelial cell membranes</article-title><source>J Pharmacol Exp Ther</source><year>2023</year><volume>385</volume><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1124/jpet.122.001281</pub-id><pub-id pub-id-type="pmid">36828631</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Noorani B, Chowdhury EA, Alqahtani F, Ahn Y, Nozohouri E, Zoubi S, Patel D, Wood L, Huang J, Siddique MB, Al-Ahmad A, Mehvar R, Bickel U (2023) Effects of volatile anesthetics versus ketamine on blood-brain barrier permeability via lipid-mediated alterations of endothelial cell membranes. J Pharmacol Exp Ther 385:135&#x02013;145<pub-id pub-id-type="pmid">36828631</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Ohikere</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>RJ</given-names></name></person-group><article-title>Hepatic encephalopathy: clinical manifestations</article-title><source>Clin Liver Dis</source><year>2024</year><volume>28</volume><fpage>253</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2024.01.005</pub-id><pub-id pub-id-type="pmid">38548437</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Ohikere K, Wong RJ (2024) Hepatic encephalopathy: clinical manifestations. Clin Liver Dis 28:253&#x02013;263<pub-id pub-id-type="pmid">38548437</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>P</given-names></name><name><surname>Vilstrup</surname><given-names>H</given-names></name></person-group><article-title>Cerebral effects of ammonia in liver disease: current hypotheses</article-title><source>Metab Brain Dis</source><year>2014</year><volume>29</volume><fpage>901</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1007/s11011-014-9494-7</pub-id><pub-id pub-id-type="pmid">24488230</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Ott P, Vilstrup H (2014) Cerebral effects of ammonia in liver disease: current hypotheses. Metab Brain Dis 29:901&#x02013;911<pub-id pub-id-type="pmid">24488230</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Palestine</surname><given-names>AG</given-names></name><name><surname>Brubaker</surname><given-names>RF</given-names></name></person-group><article-title>Plasma binding of fluorescein in normal subjects and in diabetic patients</article-title><source>Arch Ophthalmol</source><year>1982</year><volume>100</volume><fpage>1160</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1001/archopht.1982.01030040138025</pub-id><pub-id pub-id-type="pmid">7092661</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Palestine AG, Brubaker RF (1982) Plasma binding of fluorescein in normal subjects and in diabetic patients. Arch Ophthalmol 100:1160&#x02013;1161<pub-id pub-id-type="pmid">7092661</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Palmela</surname><given-names>I</given-names></name><name><surname>Correia</surname><given-names>L</given-names></name><name><surname>Silva</surname><given-names>RF</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>KS</given-names></name><name><surname>Brites</surname><given-names>D</given-names></name><name><surname>Brito</surname><given-names>MA</given-names></name></person-group><article-title>Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro study</article-title><source>Front Neurosci</source><year>2015</year><volume>9</volume><fpage>80</fpage><pub-id pub-id-type="doi">10.3389/fnins.2015.00080</pub-id><pub-id pub-id-type="pmid">25821432</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Palmela I, Correia L, Silva RF, Sasaki H, Kim KS, Brites D, Brito MA (2015) Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro study. Front Neurosci 9:80<pub-id pub-id-type="pmid">25821432</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>S</given-names></name><name><surname>Dhiman</surname><given-names>RK</given-names></name><name><surname>Duseja</surname><given-names>A</given-names></name><name><surname>Chawla</surname><given-names>YK</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name></person-group><article-title>Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy</article-title><source>Hepatology</source><year>2007</year><volume>45</volume><fpage>549</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1002/hep.21533</pub-id><pub-id pub-id-type="pmid">17326150</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007) Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45:549&#x02013;559<pub-id pub-id-type="pmid">17326150</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>M</given-names></name><name><surname>McMillin</surname><given-names>M</given-names></name><name><surname>Galindo</surname><given-names>C</given-names></name><name><surname>Frampton</surname><given-names>G</given-names></name><name><surname>Pae</surname><given-names>HY</given-names></name><name><surname>Demorrow</surname><given-names>S</given-names></name></person-group><article-title>Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms</article-title><source>Dig Liver Dis</source><year>2014</year><volume>46</volume><fpage>527</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2014.01.159</pub-id><pub-id pub-id-type="pmid">24629820</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Quinn M, McMillin M, Galindo C, Frampton G, Pae HY, Demorrow S (2014) Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. Dig Liver Dis 46:527&#x02013;534<pub-id pub-id-type="pmid">24629820</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname><given-names>NR</given-names></name><name><surname>Dziegielewska</surname><given-names>KM</given-names></name><name><surname>Mollgard</surname><given-names>K</given-names></name><name><surname>Habgood</surname><given-names>MD</given-names></name></person-group><article-title>Markers for blood-brain barrier integrity: how appropriate is Evans blue in the twenty-first century and what are the alternatives?</article-title><source>Front Neurosci</source><year>2015</year><volume>9</volume><fpage>385</fpage><pub-id pub-id-type="doi">10.3389/fnins.2015.00385</pub-id><pub-id pub-id-type="pmid">26578854</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Saunders NR, Dziegielewska KM, Mollgard K, Habgood MD (2015) Markers for blood-brain barrier integrity: how appropriate is Evans blue in the twenty-first century and what are the alternatives? Front Neurosci 9:385<pub-id pub-id-type="pmid">26578854</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Shaik</surname><given-names>IH</given-names></name><name><surname>Miah</surname><given-names>MK</given-names></name><name><surname>Bickel</surname><given-names>U</given-names></name><name><surname>Mehvar</surname><given-names>R</given-names></name></person-group><article-title>Effects of short-term portacaval anastomosis on the peripheral and brain disposition of the blood-brain barrier permeability marker sodium fluorescein in rats</article-title><source>Brain Res</source><year>2013</year><volume>1531</volume><fpage>84</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2013.07.040</pub-id><pub-id pub-id-type="pmid">23916670</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Shaik IH, Miah MK, Bickel U, Mehvar R (2013) Effects of short-term portacaval anastomosis on the peripheral and brain disposition of the blood-brain barrier permeability marker sodium fluorescein in rats. Brain Res 1531:84&#x02013;93<pub-id pub-id-type="pmid">23916670</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Spigelman</surname><given-names>MK</given-names></name><name><surname>Zappulla</surname><given-names>RA</given-names></name><name><surname>Malis</surname><given-names>LI</given-names></name><name><surname>Holland</surname><given-names>JF</given-names></name><name><surname>Goldsmith</surname><given-names>SJ</given-names></name><name><surname>Goldberg</surname><given-names>JD</given-names></name></person-group><article-title>Intracarotid dehydrocholate infusion: a new method for prolonged reversible blood-brain barrier disruption</article-title><source>Neurosurgery</source><year>1983</year><volume>12</volume><fpage>606</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1227/00006123-198306000-00002</pub-id><pub-id pub-id-type="pmid">6877542</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Spigelman MK, Zappulla RA, Malis LI, Holland JF, Goldsmith SJ, Goldberg JD (1983) Intracarotid dehydrocholate infusion: a new method for prolonged reversible blood-brain barrier disruption. Neurosurgery 12:606&#x02013;612<pub-id pub-id-type="pmid">6877542</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>PA</given-names></name><name><surname>Farrell</surname><given-names>CR</given-names></name><name><surname>Holash</surname><given-names>JA</given-names></name><name><surname>Elliot</surname><given-names>D</given-names></name><name><surname>Neiman</surname><given-names>J</given-names></name><name><surname>Resch</surname><given-names>L</given-names></name><name><surname>Carlen</surname><given-names>PL</given-names></name></person-group><article-title>Effect of bile duct ligation-induced liver damage on the blood-brain barrier</article-title><source>Can J Neurol Sci</source><year>1989</year><volume>16</volume><fpage>451</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1017/S0317167100029589</pub-id><pub-id pub-id-type="pmid">2804810</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Stewart PA, Farrell CR, Holash JA, Elliot D, Neiman J, Resch L, Carlen PL (1989) Effect of bile duct ligation-induced liver damage on the blood-brain barrier. Can J Neurol Sci 16:451&#x02013;452<pub-id pub-id-type="pmid">2804810</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>DW</given-names></name><name><surname>Elmquist</surname><given-names>WF</given-names></name></person-group><article-title>Effect of probenecid on fluorescein transport in the central nervous system using in vitro and in vivo models</article-title><source>Pharm Res</source><year>2001</year><volume>18</volume><fpage>1542</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1023/A:1013074229576</pub-id><pub-id pub-id-type="pmid">11758761</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Sun H, Miller DW, Elmquist WF (2001) Effect of probenecid on fluorescein transport in the central nervous system using in vitro and in vivo models. Pharm Res 18:1542&#x02013;1549<pub-id pub-id-type="pmid">11758761</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Tateishi</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Nakura</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Kumai</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name></person-group><article-title>Liver damage induced by bile duct ligation affects CYP isoenzymes differently in rats</article-title><source>Pharmacol Toxicol</source><year>1998</year><volume>82</volume><fpage>89</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0773.1998.tb01403.x</pub-id><pub-id pub-id-type="pmid">9498237</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Tateishi T, Watanabe M, Nakura H, Tanaka M, Kumai T, Kobayashi S (1998) Liver damage induced by bile duct ligation affects CYP isoenzymes differently in rats. Pharmacol Toxicol 82:89&#x02013;92<pub-id pub-id-type="pmid">9498237</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Tranah</surname><given-names>TH</given-names></name><name><surname>Vijay</surname><given-names>GK</given-names></name><name><surname>Ryan</surname><given-names>JM</given-names></name><name><surname>Shawcross</surname><given-names>DL</given-names></name></person-group><article-title>Systemic inflammation and ammonia in hepatic encephalopathy</article-title><source>Metab Brain Dis</source><year>2013</year><volume>28</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/s11011-012-9370-2</pub-id><pub-id pub-id-type="pmid">23224356</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Tranah TH, Vijay GK, Ryan JM, Shawcross DL (2013) Systemic inflammation and ammonia in hepatic encephalopathy. Metab Brain Dis 28:1&#x02013;5<pub-id pub-id-type="pmid">23224356</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>DM</given-names></name><name><surname>Vilaseca</surname><given-names>M</given-names></name><name><surname>Lafoz</surname><given-names>E</given-names></name><name><surname>Garcia-Caldero</surname><given-names>H</given-names></name><name><surname>Haute</surname><given-names>GV</given-names></name><name><surname>Fernandez-Iglesias</surname><given-names>A</given-names></name><name><surname>de Oliveira</surname><given-names>JR</given-names></name><name><surname>Garcia-Pagan</surname><given-names>JC</given-names></name><name><surname>Bosch</surname><given-names>J</given-names></name><name><surname>Gracia-Sancho</surname><given-names>J</given-names></name></person-group><article-title>Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension</article-title><source>Gastroenterology</source><year>2018</year><volume>155</volume><fpage>1564</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.07.022</pub-id><pub-id pub-id-type="pmid">30055171</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Tripathi DM, Vilaseca M, Lafoz E, Garcia-Caldero H, Haute GV, Fernandez-Iglesias A, de Oliveira JR, Garcia-Pagan JC, Bosch J, Gracia-Sancho J (2018) Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension. Gastroenterology 155:1564&#x02013;1577<pub-id pub-id-type="pmid">30055171</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Wahler</surname><given-names>JB</given-names></name><name><surname>Swain</surname><given-names>MG</given-names></name><name><surname>Carson</surname><given-names>R</given-names></name><name><surname>Bergasa</surname><given-names>NV</given-names></name><name><surname>Jones</surname><given-names>EA</given-names></name></person-group><article-title>Blood-brain barrier permeability is markedly decreased in cholestasis in the rat</article-title><source>Hepatology</source><year>1993</year><volume>17</volume><fpage>1103</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1002/hep.1840170625</pub-id><pub-id pub-id-type="pmid">8514260</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Wahler JB, Swain MG, Carson R, Bergasa NV, Jones EA (1993) Blood-brain barrier permeability is markedly decreased in cholestasis in the rat. Hepatology 17:1103&#x02013;1108<pub-id pub-id-type="pmid">8514260</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Lv</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name></person-group><article-title>Tumor necrosis factor-alpha affects blood-brain barrier permeability in acetaminophen-induced acute liver failure</article-title><source>Eur J Gastroenterol Hepatol</source><year>2011</year><volume>23</volume><fpage>552</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1097/MEG.0b013e3283470212</pub-id><pub-id pub-id-type="pmid">21593677</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Wang W, Lv S, Zhou Y, Fu J, Li C, Liu P (2011) Tumor necrosis factor-alpha affects blood-brain barrier permeability in acetaminophen-induced acute liver failure. Eur J Gastroenterol Hepatol 23:552&#x02013;558<pub-id pub-id-type="pmid">21593677</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><citation-alternatives><element-citation id="ec-CR61" publication-type="book"><person-group person-group-type="author"><name><surname>Waxman</surname><given-names>DJ</given-names></name><name><surname>Chang</surname><given-names>TK</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Phillips</surname><given-names>IR</given-names></name><name><surname>Shephard</surname><given-names>EA</given-names></name></person-group><article-title>Use of 7-ethoxycoumarin to monitor multiple enzymes in the human CYP1, CYP2, and CYP3 families</article-title><source>Cytochrome P450 protocols methods in molecular biology</source><year>2006</year><publisher-loc>Totowa</publisher-loc><publisher-name>Humana Press</publisher-name><fpage>153</fpage><lpage>156</lpage></element-citation><mixed-citation id="mc-CR61" publication-type="book">Waxman DJ, Chang TK (2006) Use of 7-ethoxycoumarin to monitor multiple enzymes in the human CYP1, CYP2, and CYP3 families. In: Phillips IR, Shephard EA (eds) Cytochrome P450 protocols methods in molecular biology, vol 320. Humana Press, Totowa, pp 153&#x02013;156</mixed-citation></citation-alternatives></ref><ref id="CR62"><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>KC</given-names></name><name><surname>Huang</surname><given-names>HC</given-names></name><name><surname>Chang</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Chuang</surname><given-names>CL</given-names></name><name><surname>Hsin</surname><given-names>IF</given-names></name><name><surname>Hsu</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>FY</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>SD</given-names></name></person-group><article-title>Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats</article-title><source>Eur J Pharmacol</source><year>2018</year><volume>824</volume><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2018.02.016</pub-id><pub-id pub-id-type="pmid">29444470</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Wu KC, Huang HC, Chang T, Lee WS, Chuang CL, Hsin IF, Hsu SJ, Lee FY, Chang CC, Lee SD (2018) Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats. Eur J Pharmacol 824:133&#x02013;139<pub-id pub-id-type="pmid">29444470</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>L</given-names></name></person-group><article-title>Roles of bile acids signaling in neuromodulation under physiological and pathological conditions</article-title><source>Cell Biosci</source><year>2023</year><volume>13</volume><fpage>106</fpage><pub-id pub-id-type="doi">10.1186/s13578-023-01053-z</pub-id><pub-id pub-id-type="pmid">37308953</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Xing C, Huang X, Wang D, Yu D, Hou S, Cui H, Song L (2023) Roles of bile acids signaling in neuromodulation under physiological and pathological conditions. Cell Biosci 13:106<pub-id pub-id-type="pmid">37308953</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Ling</surname><given-names>ZL</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Shu</surname><given-names>N</given-names></name><name><surname>Zhong</surname><given-names>ZY</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Di</surname><given-names>XY</given-names></name><name><surname>Wang</surname><given-names>ZJ</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>XD</given-names></name></person-group><article-title>Unconjugated bilirubin elevation impairs the function and expression of breast cancer resistance protein (BCRP) at the blood-brain barrier in bile duct-ligated rats</article-title><source>Acta Pharmacol Sin</source><year>2016</year><volume>37</volume><fpage>1129</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1038/aps.2016.25</pub-id><pub-id pub-id-type="pmid">27180978</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Xu P, Ling ZL, Zhang J, Li Y, Shu N, Zhong ZY, Chen Y, Di XY, Wang ZJ, Liu L, Liu XD (2016) Unconjugated bilirubin elevation impairs the function and expression of breast cancer resistance protein (BCRP) at the blood-brain barrier in bile duct-ligated rats. Acta Pharmacol Sin 37:1129&#x02013;1140<pub-id pub-id-type="pmid">27180978</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>AE</given-names></name><name><surname>Ede</surname><given-names>RJ</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name></person-group><article-title>Experimental studies of blood brain barrier permeability in acute hepatic failure</article-title><source>Hepatology</source><year>1984</year><volume>4</volume><fpage>359</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1002/hep.1840040302</pub-id><pub-id pub-id-type="pmid">6373548</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Zaki AE, Ede RJ, Davis M, Williams R (1984) Experimental studies of blood brain barrier permeability in acute hepatic failure. Hepatology 4:359&#x02013;363<pub-id pub-id-type="pmid">6373548</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>